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Abstract 
Panic Disorder (PD) affects about 7.9 million Europeans, with women affected 
twice as likely as men, causing substantial suffering and high economic costs. The 
etiopathogenesis of PD remains largely unknown, but both genetic and 
environmental factors contribute to risk. PD constitutes a strong psychological 
stressor, and it is therefore an important risk factor for accelerated aging. It is 
known that environmental factors can influence DNA methylation, and 
epigenetic regulation of genomic functions has been related to increased 
susceptibility for psychiatric disorders like PD.  Therefore, an Epigenome-Wide 
Association Study (EWAS) was conducted in the MPIP Panic Cohort I to compare 
medication-free PD patients (n=89) with healthy controls (n=76) stratified by sex. 
Replication was sought in an independent sample (MPIP Panic Cohort II) 
consisting of 131 cases and 169 controls, and functional analyses were 
conducted in a third sample (MPIP Dexamethasone Treatment Study, N=71). 
DNA methylation was assessed in whole blood using the Infinium 
HumanMethylation450 BeadChip and epigenetic age was calculated with the 
Horvath DNA methylation-based predictor of aging. One genome-wide 
association surviving FDR of 5% (cg07308824, P=1.094 x 10-7, P-adj=0.046) was 
identified in female PD patients (N=49) compared to controls (N=48). The same 
locus, located in an enhancer region of the HECA gene, was also 
hypermethylated in female PD patients in the replication sample (P=0.035) and 
the significance of the association improved in the meta-analysis (P-adj=0.004). 
Methylation at this CpG site was associated with HECA mRNA expression in 
another independent female sample (N=71) both at baseline (P=0.046) and after 
induction by dexamethasone (P=0.029). 5 of 15 candidates previously reported 
as associated with PD or anxiety traits also showed differences in DNA 
methylation after gene-wise correction and included SGK1, FHIT, ADCYAP1, 
HTR1A, HTR2A. Epigenetic age was accelerated in PD patients with agoraphobia 
of the MPIP Panic Cohort II compared to PD patients without, and effects were 
stronger in females. Our study examines epigenome-wide differences in PD 
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patients and epigenetic age acceleration in peripheral blood for PD. Our results 
point to possible sex-specific methylation changes in the HECA gene for PD and 
suggest age acceleration in PD patients with agoraphobia but overall highlight 
that this disorder is not associated with extensive changes in DNA methylation in 
peripheral blood. 
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1. Introduction 
Anxiety is a normal reaction to stress and can even be beneficial in some 
situations. Anxiety disorders differ from normal feelings of nervousness or 
anxiousness, often stress-induced, by being persistent (e.g. typically lasting 6 
months or more) and involving excessive fear or anxiety that can interfere with 
the ability of leading a normal life (American Psychiatric Association, 2013). 
Anxiety disorders are the most common type of psychiatric disorders and affect 
nearly 30 percent of adults (Kessler et al., 2007; Craske and Stein, 2016). Despite 
the high prevalence rates, anxiety disorders are often under-recognized and 
under-treated. According to the Diagnostic and Statistical Manual of Mental 
Disorders, 5th Edition (American Psychiatric Association, 2013), anxiety disorders 
include:   
 
1) Panic Disorder (PD) 
2) Agoraphobia 
3) Separation Anxiety Disorder 
4) Social Anxiety Disorder (Social Phobia) 
5) Specific Phobia 
6) Selective Mutism 
7) Generalized Anxiety Disorder (GAD) 
 
Anxiety disorders tend to be highly comorbid with each other, but they can be 
differentiated by close examinations since they differ from one another in the 
types of objects or situations that induce fear, anxiety or avoidance behaviour, 
and the associated cognitive ideation (American Psychiatric Association, 2013).  
Many of the anxiety disorders develop in childhood, tend to persist if not 
treated, and occur more frequently in females than in males (approximately 2:1 
ratio) (American Psychiatric Association, 2013). Anxiety disorders represent a 
heterogeneous group of disorders, probably with no single unifying etiology.  
Introduction 
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 Panic Disorder 
Panic Disorder (PD) is the most disabling anxiety disorder, causing substantial 
suffering and high economic and social costs. It affects about 7.9 million 
Europeans with women being twice as likely to be affected as men (Wittchen et 
al., 2011). PD is characterized by sudden episodes of acute anxiety (panic attacks) 
occurring without any apparent reason. It can be accompanied by a persistent 
concern of having additional attacks or worry about the possible consequences 
of the attacks (e.g. suffering of a heart attack, dying, losing control) and 
significant behavioural changes to avoid future panic attacks (Table 1) (Goodwin 
et al., 2005) .  First onset for PD is in adolescence and early adulthood  and it is 
highly comorbid with other mental disorders, especially agoraphobia (Noyes et 
al., 1986). Despite the substantial long-term disability, PD appears to be under-
diagnosed and under-treated in mental health settings. According to the DSM-5 
“Panic disorder is associated with high levels of social, occupational, and physical 
disability, considerable economic costs, and the highest number of medical visits 
among the anxiety disorders, although the effects are strongest with the 
presence of agoraphobia. Panic attacks and a diagnosis of panic disorder in the 
past 12 months are related to a higher rate of suicide attempts and suicidal 
ideation  even when comorbidity and a history of childhood abuse and other 
suicide risk factors are taken into account” (American Psychiatric Association, 
2013). Early to middle 20s is the typical mean age of onset and a small number of 
cases begin in childhood. Onset after age 45 years is unusual but can occur 
(American Psychiatric Association, 2013). 
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Table 1. Diagnostic criteria for panic disorder. The table is based on DSM-5 
(American Psychiatric Association, 2013). 
  
 
  
 
 
A. Recurrent unexpected panic attacks 
A panic attack is an abrupt surge of intense fear or intense discomfort that 
reaches a peak within minutes, 
and during which time four (or more) of the following symptoms occur: 
1. Palpitations, pounding heart, or accelerated heart rate 
2. Sweating 
3. Trembling or shaking 
4. Sensations of shortness of breath or smothering 
5. Feelings of choking 
6. Chest pain or discomfort 
7. Nausea or abdominal distress 
8. Feeling dizzy, unsteady, light-headed, or faint 
9. Chills or heat sensations 
10. Paresthesias (numbness or tingling sensations) 
11. Derealization (feelings of unreality) or depersonalization (being detached from 
oneself) 
12. Fear of losing control or „going crazy“ 
13. Fear of dying 
B. At least one of the attacks has been followed by 1 month (or more) of one or 
both of the following: 
1. Persistent concern or worry about additional panic attacks or their 
consequences (e.g. losing control,  
having a heart attack, “going crazy”) 
2. A significant maladaptive change in behavior related to the attacks (e.g. 
behaviors designed to avoid 
having panic attacks, such as avoidance of exercise or unfamiliar situations) 
C. The disturbance is not attributable to the physiological effects of a substance 
(e.g. a drug of abuse,  
a medication) or another medical condition (e.g. hyperthyroidism, 
cardiopulmonary disorders) 
D. The disturbance is not better explained by another mental disorder (e.g. the 
panic attacks do not occur 
only in response  to feared social situations, as in social anxiety disorder; in 
response to circumscribed phobic  
objects or situations, as in specific phobia; in response to obsessions, as in 
obsessive-compulsive disorder; 
in response to reminders of traumatic events, as in posttraumatic stress 
disorder; or in response to separation  
from attachment figures, as in separation anxiety disorder) 
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 Risk and Prognostic Factors 
The APA classifies the risk factors that can influence the onset of panic disorder 
in three main categories and describes them as follows (American Psychiatric 
Association, 2013): 
1. Temperamental: negative affectivity (neuroticism) (i.e., proneness to 
experiencing negative emotions) and anxiety sensitivity (i.e., the 
disposition to believe that symptoms of anxiety are harmful) are risk 
factors for the onset of panic attacks.  
2. Environmental: sexual and physical abuse during childhood are more 
common in PD compared to other anxiety disorders. Smoking 
represents also a risk factor for panic attacks and panic disorder. 
3. Genetic and physiological: It is believed that multiple genes confer 
vulnerability to panic disorder. However, the exact genes, gene 
products, or functions related to the genetic regions implicated 
remain unknown. Current neural systems models for panic disorder 
emphasize the amygdala and related structures, much as in other 
anxiety disorders. There is an increased risk for panic disorder among 
offspring of parents with anxiety, depressive, and bipolar disorders. 
Respiratory disturbance, such as asthma, is associated with panic 
disorder, in terms of past history, comorbidity, and family history 
(American Psychiatric Association, 2013). 
 
 Sex-Related Diagnostic Issues 
Relevant differences in the clinical features between males and females are not 
described so far. However, there is some evidence for sexual dimorphism, with 
an association between panic disorder and the catechol-O-methyltransferase 
(COMT) gene in females only (American Psychiatric Association, 2013). 
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 Agoraphobia 
The essential feature of agoraphobia is anxiety about being in places or 
situations from which escape might be difficult (or embarrassing) or in which 
help may not be available in the event of having a panic attack or panic-like 
symptoms (School of Health and Related Research (ScHARR), 2004). This leads to 
a pervasive avoidance of a variety of situations that may include: using public 
transportation, being in open spaces, being in enclosed places, standing in line or 
being in a crowd, being outside of the home alone in other situations (American 
Psychiatric Association, 2013). In most severe forms, agoraphobia can cause 
individuals to become completely home-bound, unable to leave their home and 
dependent on others for services or assistance to provide even for basic needs 
(American Psychiatric Association, 2013). 
Agoraphobia is diagnosed irrespectively of the presence of panic disorder. The 
percentage of individuals with agoraphobia reporting panic attacks or panic 
disorder preceding the onset of agoraphobia ranges from 30% in community 
samples to more than 50% in clinical samples (American Psychiatric Association, 
2013). The majority of individuals with panic disorder show signs of anxiety and 
agoraphobia before the onset of panic disorder. Every year approximately 1.7% 
of adolescents and adults have a diagnosis of agoraphobia. Females are twice as 
likely as males to be affected. Agoraphobia may occur in childhood, but 
incidence peaks in late adolescence and early adulthood. In two-thirds of all 
cases of agoraphobia, initial onset is before 35 years. Heritability for agoraphobia 
ranges up to 61% (American Psychiatric Association, 2013). Negative events in 
childhood (e.g. separation, death of parent) and other stressful events, such as 
being attacked or mugged, are associated with the onset of agoraphobia. The 
majority of individuals with agoraphobia also have other mental disorders, most 
frequently other anxiety disorders (e.g. specific phobias, panic disorder, and 
social anxiety disorder), depressive disorders (MDD), PTSD, and alcohol use 
disorder. Whereas other anxiety disorders (e.g. panic disorder) frequently 
precede onset of agoraphobia, depressive disorders and substance use disorders 
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typically occur secondary to agoraphobia (American Psychiatric Association, 
2013). 
 
 Pathophysiology of Anxiety Disorders 
Two are the most acknowledged contributors to psychopathology: genetic 
vulnerability and environmental stressors.  
Several approaches have been used to define the genetic contribution to 
psychiatric disorders like anxiety disorders, including family studies, twin studies, 
linkage studies, association studies, GxE studies, molecular, cellular and clinical 
studies (Figure 1).  
 
 Genetic Risk Factors 
 Family and Twin Studies 
Family and twin studies provided consistent evidence that panic disorder is 
familiar and heritable. The overall heritability of PD is substantial with heritability 
estimates up to 48% (Hettema et al., 2001).  
 
 Linkage Studies 
Having established that genetic factors influence PD, many linkage studies have 
been performed to map the relevant loci. Linkage analysis have implicated 
several chromosomal regions (Smoller et al., 2008) and the strongest evidence 
was found for the 13q locus when the phenotype was defined as a syndrome 
that included PD as well as several other medical conditions (mitral valve 
prolapse, serious headaches, and/or thyroid problems) (Weissman et al., 2000; 
Hamilton et al., 2003). 
In the largest analysis to date, Fyer et al. reported genome-wide significant 
linkage to 15q using a broad panic phenotype that included sporadic and limited 
symptom panic attacks in addition to PD (Fyer et al., 2006). However, there has 
been little consistency in linkage scans for PD (Smoller et al., 2008). 
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Figure 1. Summary of psychiatric genetics methods. Source: Smoller (2016) 
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 Genome-Wide Genetic Associations 
Genome-wide association studies (GWAS) enable a so-called “unbiased” search 
for risk loci by examining variants across the genome instead of limiting the 
search to hypothesized candidates (as in candidate gene studies) (Smoller, 2016). 
The first GWAS of PD was published in 2009 (Otowa et al., 2009), included 200 
cases and 200 controls of the Japanese population and reported significant 
variants in TMEM16B and PKP1, but these findings could not be replicated by the 
same investigators in a larger independent sample (Otowa et al., 2010; Smoller, 
2016). However, more robust support has emerged for transmembrane protein 
132D (TMEM132D) in three independent samples consisting of a total of 909 
cases and 915 controls. Risk genotypes identified in this study were associated 
with higher TMEM132D mRNA expression in human post-mortem frontal cortex.  
These results were further supported by a mouse model in which high anxiety-
related behaviour was associated with a TMEM132D SNP and correlated with 
expression of TMEM132D mRNA in the anterior cingulate cortex (Erhardt et al., 
2011). It has been suggested that this gene has a role in threat processing, but its 
function is not fully understood (Haaker et al., 2014; Smoller, 2016). 
This study had an adequate power to detect the reported effect size of OR 1.4 in 
the combined sample of 909 cases, even if the size of the discovery sample was 
modest. In complex psychiatric disorders genetic effect sizes of this magnitude 
are probably the exception, therefore more modest effects in other important 
genes might have been missed (Wellcome Trust Case Control Consortium, 2007; 
Baum et al., 2008; Erhardt et al., 2011). A summary of GWAS of anxiety disorders 
is reported in Table 2.  
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Table 2. GWAS of anxiety disorders. Source: Shimada-Sugimoto et al. (2015)  
 
Reference Phenotype Dataset Most 
significant 
finding 
P-value OR 
(Otowa et 
al., 2009; 
Otowa et 
al., 2010) 
PD 200 cases, 
200 controls  
(GWAS); 558 
cases, 566 
controls 
(Replication) 
TMEM16B 
(12p13) 
3.73x10-9 
(GWAS); NS 
(Replication) 
22.1 
(Erhardt et 
al., 2011) 
PD 216 cases, 222 
controls (GWAS); 
693 cases, 693 
controls 
(Replication) 
TMEM132D 
(12q24) 
7.73 x 10-7 
(GWAS); 1.36 
x 10-6 (all 
samples) 
2.2 
(Otowa et 
al., 2012) 
PD 718 cases, 1717 
controls (GWAS); 
329 cases, 861 
controls 
(Replication) 
BDRKB2 
(14q32) 
4.43 x 10-6 
(GWAS); 1.32 
x 10-5 (all 
samples) 
1.31 
(Kawamura 
et al., 
2011) 
PD 535 cases, 1520 
controls 
(genome-wide 
copy number 
variation 
analysis) 
Common 
duplication 
(16p11.2) 
3.5 x 10-6 2.35 
(Trzaskows
ki et al., 
2013) 
Anxiety-
related 
behaviours 
2810 7-year-old 
children (GWAS); 
4804 children 
(Replication) 
STXBP6, 
NOVA1 
(14q12) 
(Negative 
Cognition); 
CAP2 
(6p22.3)  
(Anxiety 
Composite) 
4.12 x 10-7 
(Negative 
Cognition); 
6.27 x 10-7 
(Anxiety 
Composite) 
- 
(Schosser 
et al., 
2013; 
Otowa et 
al., 2014) 
Anxiety in 
MDD 
1522 MDD (1080 
with anxiety) 
cases, 1588 
controls 
DSCAM 
(21q22.2) 
3.27 x 10-7 1.53 
(Otowa et 
al., 2014) 
GAD, PD, 
agoraphobi
a, social 
phobia, 
specific 
phobia 
2540 European 
Americans, 849 
African 
Americans 
MFAP3L 
(4q32.3) 
8.63 x 10-7 - 
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 Environmental Risk Factors  
Psychiatric disorders are multifactorial diseases that emerge through the 
interplay between environmental factors and genetic predisposition. The aim of 
gene-by-environment interaction (GxE) studies is exactly to determine the extent 
to which genetic predisposition in combination with environmental determinants 
shapes the risk for psychiatric disorders (Halldorsdottir and Binder, 2017). 
Different hypothesis have been developed over the years to explain how genes 
and environment contribute to disease risk. According to the “diathesis-stress” 
hypothesis, genes and adversity, independently and in combination, increase the 
liability to disorder (Smoller, 2016). This model however focuses only on negative 
environmental influences. An alternative model, known as the differential-
susceptibility perspective, has been proposed by Belsky and colleagues (Belsky et 
al., 2007; Belsky and Pluess, 2009). According to the latter, no genotype is 
inherently good or bad, but individuals vary in their susceptibility to both 
negative and positive environmental influences. 
 
GxE studies available so far have focused on a small number of predominantly 
functional candidate markers in a limited number of genes and no genome-wide 
search for GxE in common psychiatric disorders, including anxiety disorders (AD), 
has been conducted (Shimada-Sugimoto et al., 2015). The lack of such studies in 
this field is due to the need of larger samples and of a more precise definition of 
“environmental” or “candidate stressors” (Klauke et al., 2010), which are very 
important factors for the design of future genome-wide GxE studies in AD. 
 
Epidemiologic and twin studies (Kendler et al., 2016; South et al., 2016; Torvik et 
al., 2016) support the importance of adverse events occurring early in life in 
increasing the risk for psychiatric disorders, including mood and anxiety 
disorders but also psychoses and personality disorders (Kessler et al., 2010; 
Binder, 2017). Adverse life events have been shown to associate with specific 
epigenetic modifications, such as DNA methylation, which may mediate the 
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lasting cellular consequences of these exposures in psychiatric disorders (Slatkin, 
2009), also in the context of GxE (Klengel and Binder, 2015). 
 
 Epigenetics 
The word “epigenetic” literally means “in addition to changes in genetic 
sequence”. The term has evolved to include any process that alters gene activity 
without changing the DNA sequence, and leads to modifications that can be 
transmitted to daughter cells (although experiments show that some epigenetic 
changes can be reversed) (Weinhold, 2006). Epigenetic modifications are 
heritable changes in gene expression not encoded by the DNA sequence. They 
include DNA methylation, the histone code, noncoding RNA, and nucleosome 
positioning, along with DNA sequence. Epigenetic processes are natural and 
essential to many organism functions, but if they occur improperly, there can be 
major adverse health and behavioural effects. 
DNA methylation, catalysed by the DNA methyltransferases (DNMTs), is 
considered a key player in epigenetic silencing of transcription and is one of the 
most studied epigenetic modifications in human cells. Changes in DNA 
methylation patterns play a critical role in development, differentiation and 
diseases such as multiple sclerosis, diabetes, schizophrenia, aging, and multiple 
forms of cancer (Bibikova et al., 2011).  
DNA methylation may regulate the chromatin status via the interaction of 
DNMTs together with other modifications and with components of the 
machinery mediating those marks (Jin et al., 2011). 
 
 DNA Methylation 
DNA methylation is a heritable epigenetic mark involving the covalent transfer of 
a methyl group to the C-5 position of the cytosine ring (Figure 2) of DNA by DNA 
methyltransferases (DNMTs) (Robertson, 2005).  
In mammals, DNA methylation occurs at cytosines in any context of the genome 
(Lister et al., 2009). However, more than 98% of DNA methylation occurs in a 
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CpG dinucleotide context in somatic cells, while as much as a quarter of all 
methylation appears in a non-CpG context in embryonic stem  cells (ESCs) (Lister 
et al., 2009). DNA methylation is typically removed during zygote formation and 
then re-established in the embryo at approximately the time of implantation 
(Zhu, 2009). Most DNA methylation is essential for normal development, and it 
plays a very important role in a number of key processes including genomic 
imprinting, X-chromosome inactivation, and suppression of repetitive element 
transcription and transposition and, when dysregulated, contributes to diseases 
like cancer (Robertson, 2005; Gopalakrishnan et al., 2008; Jin et al., 2008; Jin et 
al., 2009). 
The methylation pattern in mammalian genomes is bimodal, with most of the 
genomes methylated except for short DNA stretches called CpG islands (CGIs), 
which are generally protected from methylation (Siegfried and Simon, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. DNA methylation 
Modified from: http://www.ks.uiuc.edu/Research/methylation/ 
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 CpG Islands 
CpG islands were first described 30 years ago (Bird, 1986). In mammals CpG 
dinucleotides are under-represented in the genome with the exception of short 
DNA stretches called CGIs. This uneven distribution is also associated with a 
bimodal pattern of cytosine methylation (almost all CpG dinucleotides are 
methylated with the general exception of CGIs). The higher CpG density in the 
unmethylated CGIs is probably due to the lower mutation rate of unmethylated 
cytocines. Deamination of cytosines in methylated CpG dinucleotides produces 
thymine, which is stable, whereas deamination of unmethylated cytosine 
produces uracil, which can be removed by uracil glycosylase. The consequence is 
that unmethylated regions maintain their CpG density whereas methylated 
regions lose their CpG density due to mutations. Indeed, CpGs located within 
CGIs are more highly conserved between human and chimpanzee. Moreover, 
even among CGIs, methylated islands have diverged at faster rates than the 
nonmethylated CGIs (Siegfried and Simon, 2010). 
DNA methylation across CpG sites in the genome is typically regarded as 
bimodal, with CpG-rich regions known as CpG islands, often associated with 
transcription start sites (TSSs), typically showing hypomethylation, and other CpG 
sites showing hypermethylation (Wagner et al., 2014). 
 
 DNA Methylation and Gene Expression 
The relationship between methylation and gene expression is complex, with high 
levels of gene expression often associated with low promoter methylation (Kass 
et al., 1997) (Figure 3) but elevated gene body methylation (Jones, 1999), and 
the causality relationships have not yet been determined (Wagner et al., 2014).  
Methylation has been shown to be highly variable across cell types with variable 
sites falling in two broad categories: those with inverse correlation between DNA 
methylation and chromatin accessibility and constitutive DNA hypomethylation 
(Thurman et al., 2012). In the study of (Wagner et al., 2014), CpG probes where 
methylation levels correlated negatively with gene expression were for the most 
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part located in regions with marks of regulatory activity (H3K4me3 or DHS). In 
contrast, positively correlated probes were slightly more often seen with the 
inactive gene-associated marker H3K27me3 when compared with negatively 
correlated probes (Wagner et al., 2014). 
 
 
 
 
Figure 3. Consequences of DNA methylation on gene expression 
Source: http://missinglink.ucsf.edu/lm/genes_and_genomes/methylation.html 
 
 
 
 Epigenome-Wide Association Studies  
Although the genome gives information about genome sequence and structure, 
the human epigenome provides functional aspects of the genome. Epigenome-
wide association studies (EWAS) provide an opportunity to identify genome-wide 
epigenetic variants that could be associated with human phenotypes (Verma, 
2012; Flanagan, 2015). The epigenome is especially intriguing as a target for 
study, as epigenetic regulatory processes are, by definition, heritable from 
parent to daughter cells and are found to have transcriptional regulatory 
properties. As such, the epigenome is an attractive candidate for mediating long-
term responses to cellular stimuli, such as environmental effects modifying 
disease risk. When a pattern of changes of DNA methylation is found to occur 
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repeatedly at specific loci, discriminating the phenotypically affected cases from 
control individuals, this is regarded as an indication that epigenetic perturbation 
has taken place that is associated, possibly causally, with the phenotype. This 
approach is described as an epigenome-wide association study (EWAS) (Rakyan 
et al., 2011), and takes its cue from the association of genetic variability with 
phenotypes in genome-wide association studies (GWAS) (Birney et al., 2016). 
 
 Technical Background  
Epigenetic variation can contribute to the development of a disease or be a 
consequence of it (also known as reverse causality). Distinguishing between the 
two processes presents a major challenge for EWASs (Paul and Beck, 2014).  
Array-based assays have been widely adopted to study DNA methylation owing 
to their low costs, ease of use and high throughput. The Illumina Infinium 450K 
BeadChips are among such assays and have been the platform of choice for 
epigenome-wide association studies. They can quantify CpG and a very small 
fraction of non-CpG methylation at single-base resolution (Plongthongkum et al., 
2014).  
 
 Illumina 450K Array Design 
The Illumina 450K BeadChip interrogates more than 485,000 methylation sites 
per sample at single-nucleotide resolution and can analyse twelve samples in 
parallel. It covers 99% of RefSeq genes, with an average of 17 CpG sites per gene 
region distributed across the promoter, 5´ UTR, first exon, gene body, and 3´ 
UTR. It covers 96% of CpG islands, with additional coverage in island shores and 
the regions flanking them (Figure 4). Each sample is measured on a single array, 
in two different color channels (red and green) (Figure 5). For each CpG, there 
are two measurements: a methylated intensity and an unmethylated intensity. 
Depending on the probe design, the signals are reported in different colors:  
- for Type I design, both signals are measured in the same color: one probe 
for the methylated signal and one probe for the unmethylated signal. 
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- for Type II design, only one probe is used. The Green intensity measures 
the methylated signal, and the Red intensity measures the unmethylated 
signal (Bibikova et al., 2011). 
 
 
 
 
 
Figure 4. Illumina Infinium 450K BeadChip probe distribution. Source: (Bibikova 
et al., 2011) 
4A. Coverage of NM and NR transcripts from UCSC database. 
Each transcript was divided into “functional regions” — TSS200 is the region 
from Transcription start site (TSS) to − 200 nt upstream of TSS; TSS1500 covers − 
200 to − 1500 nt upstream of TSS; 5′ UTR, 1st exon, gene body and 3´ UTR were 
also covered separately. 
4B. Coverage of CpG islands and adjacent regions. 
CpG islands longer than 500 bp were divided into separate bins. The 2 kb regions 
immediately upstream and downstream of the CpG island boundaries, or “CpG 
island shores”, and the 2 kb regions upstream and downstream of the CpG island 
shores, referred to here as “CpG island shelves,” were also targeted separately. 
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Figure 5. Illumina Infinium 450K BeadChip principle. Modified from: 
https://www.illumina.com/products/methylation_450_beadchip_kits.html 
 
 
Two measures are commonly used to report methylation levels: β-values and M-
values. 
 
 
β-value: 
𝛽 =
𝑀
𝑀 + 𝑈 + 𝛼
 
 
 
where M and U denote the methylated and unmethylated signals respectively; α 
is a constant (by default, α=100) that regularizes the β-value when both 
methylated and unmethylated probe intensities are low. 
The β-value statistic results in a number between 0 and 1, or 0 and 100%. Under 
ideal conditions, a value of zero indicates that all copies of the CpG site in the 
sample were completely unmethylated (no methylated molecules were 
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measured) and a value of one indicates that every copy of the site was 
methylated (Du et al., 2010). 
 
M-value:  
 
𝑀𝑣𝑎𝑙 = 𝑙𝑜𝑔 (
𝑀
𝑈
) 
 
The M-value is calculated as the log ratio of the intensities of methylated probe 
versus unmethylated probe. 
An M-value close to 0 indicates a similar intensity between the methylated and 
unmethylated probes, which means the CpG site is about half-methylated. 
Positive M-values mean that more molecules are methylated than unmethylated, 
while negative M-values mean the opposite (Du et al., 2010). 
 
The β-value has a more intuitive biological interpretation, the M-value is on the 
other hand more statistically valid for the differential analysis of methylation 
levels (Du et al., 2010). In this thesis, M-values were used for differential 
methylation analysis and β-values to show the results.  
 
 DNA Methylation Age (Epigenetic Clock) 
DNA methylation changes during physiological processes like aging, but also 
during disease status, e.g. aging associated diseases (Bjornsson et al., 2008; 
Christensen et al., 2009; Rakyan et al., 2010; Hernandez et al., 2011; Heyn et al., 
2012; Horvath et al., 2012; Horvath, 2013).  
Considering the unprecedented growth rate of the world´s aging population, 
there is a clear need for a better understanding of the biological aging process 
and the determinants of healthy aging (Jylhava et al., 2017). Towards this aim, 
several DNA methylation-based predictors of aging have been developed  
(Bocklandt et al., 2011; Hannum et al., 2013; Horvath, 2013; Weidner et al., 
2014). Among these, a composite predictor comprised of 353 Cytosine-
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phosphate-Guanosine sites (CpGs) across the genome (‘epigenetic clock’) was 
shown to strongly correlate with chronological age across multiple tissues 
(r=0.96) in humans (Horvath, 2013) with a small mean deviation from calendar 
age (3.6 years), suggesting its usefulness as a biomarker in aging-related research 
(Zannas et al., 2015). The algorithm behind the DNA methylation age calculation 
uses a penalized regression model to predict the CpG sites and has been 
developed in 8000 samples, covering the entire adult life span and different 
ethnic populations.  
Accelerated epigenetic aging (Δ-age) calculated using this predictor, defined as 
the difference between DNA methylation-predicted age (DNAmAge) and 
chronological age, has been associated with aging-related diseases and other 
phenotypes, including cancer, obesity, cytomegalovirus infection, Down’s 
syndrome, PTSD, physical and cognitive decline, all-cause mortality, the presence 
of higher self-control, lower socioeconomic status, and lifetime stress (Horvath, 
2013; Horvath et al., 2014; Boks et al., 2015; Kananen et al., 2015; Marioni et al., 
2015b; Marioni et al., 2015a; Miller et al., 2015; Zannas et al., 2015). The 
correlation with all-cause mortality was confirmed in a study that included 13 
cohorts for a total of 13,098 individuals from three ethnic groups (Chen et al., 
2016). Moreover, epigenetic estimates that incorporated information on blood 
cell composition led to the smallest p-values for time to death (p=7.5 x 10-43). The 
latter study could strengthen the evidence that epigenetic age predicts all-cause 
mortality above and beyond chronological age and traditional risk factors.  This 
suggests that the epigenetic age of blood tissue is one of the mediating 
processes of chronological age on mortality and that this is independent of age-
dependent changes in blood cell composition.  
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2. Aims  
 
Exploring DNA methylation might give us an integrated view of both 
environmental and genetic risk factors. While epigenetic changes including DNA 
methylation are mainly tissue specific, some sites show cross tissue relevance 
(Farre et al., 2015; Hannon et al., 2015) and furthermore changes in peripheral 
tissues such as blood could serve as potential biomarker for disease risk. 
To date, a few studies have investigated differences in DNA methylation in 
candidate genes in PD (Bayles et al., 2013; Domschke et al., 2013; Prelog et al., 
2016; Ziegler et al., 2016), but genome-wide analysis of the peripheral blood 
methylome of PD patients as compared to controls are currently lacking.  To 
perform such a study in two independent samples of patients with PD vs control 
was the aim of the study. To reduce confounding due to effects of drug 
treatment, both patients and controls were free of psychotropic medication. 
Given that both the prevalence of PD as well as DNA methylation pattern show 
large sex differences (Yousefi et al., 2015), a sex-stratified analysis was 
undertaken and complemented by a meta-analysis.  
Previous studies report that hits identified in genome-wide association studies 
(GWAS) show changes in DNA methylation in peripheral blood, e.g. in 
schizophrenia (Montano et al., 2016) or bipolar disorder (Houtepen et al., 2016).  
For this reason, in addition to an unbiased approach, I also investigated DNA 
methylation changes in candidate genes that have emerged from genome-wide 
genetic studies either in humans or animals (Erhardt et al., 2011; Knoll et al., 
2016; Nieto et al., 2016). 
 
Panic disorder is known to be a strong stressor and psychological stress is an 
important risk factor for accelerated aging and aging-related diseases. PD has a 
high comorbidity rate with other psychiatric disorders like agoraphobia and 
depression, and with other medical conditions e.g. cardiovascular disorders, 
asthma, epilepsy (American Psychiatric Association, 2013). Agoraphobia 
constitutes a stronger stressor for patients with PD, therefore PD patients with 
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comorbid agoraphobia are classified as more severely ill compared to PD 
patients without (American Psychiatric Association, 2013).   
It has been proven that aging and aging-related diseases are associated with 
changes in DNA methylation (Bjornsson et al., 2008; Christensen et al., 2009; 
Rakyan et al., 2010; Hernandez et al., 2011; Heyn et al., 2012; Horvath, 2013), 
and was therefore used so far as a useful biomarker of aging-related research. 
Previous studies show indeed a correlation of DNA methylation age with 
morbidity and mortality (Horvath et al., 2015; Marioni et al., 2015b; Chen et al., 
2016; Christiansen et al., 2016).  
Given these previous findings, I wanted to investigate whether age acceleration 
is occurring in PD patients and if there is a difference among PD patients with 
agoraphobia and PD patients without. To answer these questions, I calculated 
epigenetic aging (∆-age) using the Horvath DNA methylation-based predictor 
(Horvath, 2013). 
  
24 
 
 
3. Materials and Methods 
 Samples and Study Design 
 MPIP Panic Cohort I and II 
PD patients included in the MPIP panic cohort I and II were recruited in the 
anxiety disorders outpatient unit at the Max Planck Institute of Psychiatry (MPIP) 
in Munich (Erhardt et al., 2011). PD was the primary diagnosis; mild secondary 
depression was allowed (Table 3). The diagnosis was ascertained by trained 
psychiatrists according to the Diagnostic and Statistical Manual of Mental 
Disorders DSM-IV criteria. All patients underwent the Structured Clinical 
Interviews for DSM-IV (SCID I and II). PD due to a medical or neurological 
condition or the presence of a comorbid Axis II disorder was an exclusion 
criterion. All patients included in the current analyses were not taking any 
psychotropic medications for at least 4 weeks before the blood draw and 
underwent a thorough medical examination including EEG, ECG and detailed 
hormone laboratory assessment. 
Control subjects were recruited from a Munich-based community sample and 
screened for the absence of axis I psychiatric disorders using the Munich version 
of the Composite International Diagnostic Interview (M-CIDI) (Wittchen, 1997). 
Controls were age- and sex-matched with patients.  
All subjects were Caucasian and provided written informed consent. The Ethics 
Committee of the Ludwig Maximilians University, Munich, Germany, in 
accordance with the Declaration of Helsinki approved all procedures.  
 
 MPIP Dexamethasone Treatment Study 
Glucocorticoid-induced methylation and gene expression changes were 
examined in an independent sample of 71 Caucasian female subjects (29 healthy 
probands and 42 depressed) recruited at the MPIP. Recruitment strategies and 
characterization of participants have been previously described (Arloth et al., 
2015). Baseline whole blood samples were obtained at 6 p.m. after 2 hours of 
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fasting and abstention from coffee and physical activity (baseline). Subjects then 
received 1.5 mg oral dexamethasone (DEX) and a second blood draw was 
performed at 9 p.m. three hours after DEX ingestion (post-DEX). The study was 
approved by the local ethics committee and all individuals gave written informed 
consent. 
 
 
Table 3. Characteristics of the participants included in the study 
Variable Controls Cases Total 
MPIP Panic Cohort I     
Participants, N (%) 76 (46%) 89 (54%) 165 
Male , N (%) 28 (17%) 40 (24%) 68 (41%) 
Female, N (%) 48 (29%) 49 (30%) 97 (59%) 
Age, years (SD) 37 (7.5) 36 (10.4)  
Diagnosis None PDA 72% 
PD 28% 
Comorbidity:
MDD 13.5% 
 
MPIP Panic Cohort II     
Participants, N (%) 169 (56%) 131 (44%) 300 
Male , N (%) 48 (16%) 48 (16%) 96 (32%) 
Female, N (%) 121 (40%) 83 (28%) 204 (68%) 
Age, years (SD) 38 (7.2) 38 (11.6)  
Diagnosis None PDA 61% 
PD 39% 
Comorbidity:
MDD 13% 
 
MPIP 
Dexamethasone 
Treatment Study 
   
Participants, N (%) 29 (41%) 42 (59%) 71 
Male , N (%) 0 0 0 
Female, N (%) 29  42 71 
Age, years (SD) 44 (11.4) 44 (13.7)  
Diagnosis None MDD  
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 Methylation Data 
 MPIP Panic Cohort I and II 
Genomic DNA was extracted from peripheral blood using the Gentra Puregene 
Blood Kit (Qiagen). DNA quality and quantity was assessed using NanoDrop 2000 
Spectrophotometer (Thermo Scientific) and Quant-iT Picogreen (Invitrogen). To 
minimize batch effects, samples were randomized with respect to case-control 
status, sex and age. 
Genomic DNA was bisulfite converted using the Zymo EZ-96 DNA Methylation Kit 
(Zymo Research) and DNA methylation levels were assessed for >480,000 CpG 
sites using the Illumina HumanMethylation450 BeadChip array. Hybridization and 
processing were performed according to the instructions of the manufacturer.  
 
 MPIP Dexamethasone Treatment Study 
Genomic DNA was extracted from whole blood using the Gentra Puregene Blood 
Kit (QIAGEN) and processed as for the MPIP Panic cohorts. DNA methylation 
levels were assessed for >480,000 CpG sites using the Illumina 
HumanMethylation450 BeadChip arrays.  
 
 Quality Control of Methylation Data 
 General 
The Bioconductor R package minfi (version 1.10.2) was used for the quality 
control of methylation data including intensity read outs, normalization, cell-type 
composition estimation, β- and M-value calculation. Outliers, i.e. samples whose 
behaviour deviated from that of others, were excluded from the analysis as well 
as samples with a discordant methylation-predicted vs reported sex 
(Supplementary Table S21). 
Failed probes were excluded based on a detection p-value larger than 0.01 in 
>50% of the samples. X chromosome, Y chromosome, and non-specific binding 
probes were removed (Chen et al., 2013). I also excluded probes if single 
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nucleotide polymorphisms (SNPs) were documented in the interval for which the 
Illumina probe is designed to hybridize. Probes located close (10 bp from query 
site) to a SNP, which had a minor allele frequency of ≥0.05, as reported in the 
1000 Genomes Project, were also removed. This yielded a total of around 
425,000 CpG sites in the discovery and replication sample for further analysis.  
The data were then normalized with functional normalization (FunNorm)(Fortin 
et al., 2014), an extension of quantile normalization included in the R package 
minfi. Batch effects were identified by inspecting the association of principal 
components of the methylation levels with possible technical batches using 
linear regressions and visual inspection of PCA plots using the Bioconductor R 
package shinyMethyl (version 0.99.3). Identified batch effects (i.e. bisulfite 
conversion plate and plate position) were removed using the Empirical Bayes' 
(EB) method ComBat (Johnson et al., 2007). Batch corrected M-values after 
ComBat were used for all further statistical analyses. 
 
 Biological and Non-Biological Confounders 
There is a number of other additional factors that influence data analysis which 
are not related to the scientific question that I want to answer, but rather due to 
the methodology itself, that introduces unwanted variability to the data. These 
additional factors, defined as confounders, can be classified in two main 
categories: 
1) Biological (or non-technical) confounders 
2) Non-biological (or technical) confounders 
 
 Biological Confounders 
Biological confounders include: 
1. Cell subtype proportional heterogeneity (Houseman) 
There is a potential for cell subtype proportional heterogeneity to 
influence the DNA methylation patterns observed in pools of cells. This 
was highlighted by Houseman and colleagues in a study showing that 
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altering the proportions of purified cells in a mixture generates different 
DNA methylation profiles, reflecting the distinctive DNA methylation 
patterns of each cell type present (Houseman et al., 2012). It was 
subsequently shown that cell subtype effects accounted for a major 
proportion of the epigenetic changes associated with ageing in a re-
analysis of five studies of peripheral blood leukocytes (Jaffe and Irizarry, 
2014). These findings of the influence of cell subtype heterogeneity 
prompted the development of new analytical approaches to account for 
this effect (Houseman et al., 2012; Houseman et al., 2014). Even when 
cells are “purified” using cell surface markers, (Wijetunga et al., 2014) 
found evidence for further cell subtypes with distinctive DNA methylation 
patterns. It is, therefore, likely that even when using purification 
techniques, a pool of cells is composed of multiple epigenomes, 
generating what can be defined as “meta-epigenome” (Wijetunga et al., 
2014). 
2. Age, sex and race  
In our study design and during the selection process of the samples to be 
included in the study, I already took into account that there is a sex-bias 
in the incidence of the disease (occurring panic disorder twice more often 
in females compared to males) and a difference in terms of age. I also 
considered that usually the distribution of age and sex is different in 
patients compared to healthy controls, that is why I matched cases and 
controls according to age and sex. I applied the same principle also when 
performing the experiments, and designed it in order to have the same 
ratio of males/females and a balanced age distribution across the 
methylation chips. 
 
For all these reasons, age, sex and Houseman-calculated cell count were always 
included as covariates in the regression models. As showed in the MDS plots 
(Supplementary Figure 1-2), all the individuals included in the study are 
Caucasians and there was no indication to include the PCs for ethnicity as 
covariates.   
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 Non-Biological Confounders  
„Batch effects“ are non-biological experimental variations commonly observed 
between multiple groups of samples (batches) in high-throughput experiments, 
e.g. microarray experiments, that can „confound“ the results by adding variation 
to the data, thus decreasing the statistical power to detect biological 
phenomena. For example, batch effects may occur if a subset of experiments 
was run on Monday and another set on Tuesday, if two technicians were 
responsible for different subsets of the experiments, or if two different lots of 
reagents, chips or instruments were used. 
Batch effects can be reduced through data normalization and through a good 
experimental design, i.e. the study groups have to be equally represented 
throughout the experiment (in this case in the different chips used). However 
still high levels of systematic heterogeneity in the data often remains and it can 
obscure biological phenomena under study; for this reason, it is necessary to 
correct the data for batch effects.  
There are two main ways to correct for batch effects: (1) directly removing 
known batch effects using ComBat and (2) identifying and estimating surrogate 
variables for unknown sources of variation in high-throughput experiments (Leek 
et al., 2010).  
 
 Batch Correction 
 ComBat 
ComBat uses an empirical Bayes approach to estimate and to remove batch 
effects and it also avoids over-correcting, which is critical for the use with small 
batches. Location and scale parameters, representing mean and variance, are 
estimated for each batch and each gene independently and combined with 
empirical Bayes to remove batch effects (Johnson et al., 2007). ComBat has been 
successfully applied to several datasets (Walker et al., 2008; Chen et al., 2011; 
Luo et al., 2012; Chmielewski et al., 2014), and using a single reference sample 
for each batch, its usefulness has been demonstrated for cross-sectional data 
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(Walker et al., 2008). This method assumes that the batches are known (Muller 
et al., 2016). 
 Surrogate Variable Analysis (SVA) 
In addition to the measured variable(s) of interest, there will tend to be sources 
of signal due to factors that are unknown, unmeasured, or too complicated to 
capture through simple models and this is true even for well-designed, 
randomized studies (Leek and Storey, 2007). 
Surrogate variables are covariates constructed directly from high-dimensional 
data (like gene expression/RNA sequencing/methylation/brain imaging data) that 
can be used in subsequent analyses to overcome these problems by adjusting for 
unknown, unmodeled, or latent sources of noise (Jaffe et al., 2015). 
Defining a precise biological question is a crucial step for genomics investigation 
in general, and for this type of analysis in particular. In performing SVA, effects 
specified in the model will be preserved while systematic heterogeneity is 
identified and subsequently adjusted for in subsequent statistical analysis. If our 
biological question is for example whether there is a difference between cases 
and controls, we can “protect for” case-control status and correct for the 
remaining variance. This approach has previously been shown to result in more 
accurate and stable gene rankings, improved false discovery estimation and 
correct p-value distributions (Leek and Storey, 2007, 2008; Leek et al., 2010).  
 
 Expression Data 
 MPIP Dexamethasone Treatment Study 
Whole blood RNA was collected using PAXgene Blood RNA Tubes (PreAnalytiX), 
processed as described previously (Arloth et al., 2015). Blood RNA was hybridized 
to Illumina HumanHT-12 v3 and v4 Expression BeadChips arrays. All gene 
expression array probes have been subjected to an extensive quality control 
including filtering by low p-detection value, variance stabilization and 
normalization (VSN) (Lin et al., 2008) as previously described in (Zannas et al., 
2015). Cellular composition was estimated by using CellCode (Chikina et al., 
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2015).  
 Statistical Analysis 
 MPIP Panic Cohort I and II 
 Epigenome-Wide Association Study 
Linear regression models were fit for each probe to test for a case vs control 
difference within the R package MatrixEQTL (version 2.1.1) (Shabalin, 2012). Sex, 
age and imputed white blood cell distribution from the Houseman projection 
(Houseman et al., 2012) were included as covariates. Population stratification 
was investigated using multidimensional scaling and could not be observed 
(Supplementary Figure 1-2). Significance after multiple testing was adjusted 
using false discovery rate (FDR) of 5%. As a first step all the samples of every 
cohort (Table 3) were analysed together but, given the higher prevalence of PD 
in females, I also performed a sex-stratified analysis, first in the MPIP Panic 
Cohort I and then in the MPIP Panic Cohort II. A fixed-effect meta-analysis across 
both samples was performed following identification of hits in the individual 
analyses. 
 
 Targeted Gene Analysis 
High number of studies showed mostly single SNP associations in different genes 
with PD, however, the replicability of these findings was low. Therefore, I used 
three lines of approaches to select candidate genes for the targeted methylome 
analysis:  
1) candidate genes from human genetic studies confirmed in the recent 
meta-analysis study of different international PD cohorts (TMEM132D, 
COMT, NPSR1 and HTR2A) (Howe et al., 2016), 
2) and/or having additional evidence from translational studies for anxiety 
and stress-related phenotypes (CRH, CRHR1, ADCYAP1, ADCYAP1R1, 
FKBP5, SGK1, BDNF, HTR1A) (Blaya et al., 2010; Ressler et al., 2011; 
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Konishi et al., 2014; Straube et al., 2014; Han et al., 2015; Cattaneo and 
Riva, 2016; Weber et al., 2016; Zannas et al., 2016) and lastly, 
3) genes containing loci with previous evidence for differential methylation 
in PD and anxiety disorders (GAD1, OXTR) (Domschke et al., 2013; Ziegler 
et al., 2015).  
All the genes examined (N=15) showed previous evidence of association with 
stress-related phenotypes not only in clinical (human) studies but also in 
preclinical (animal) studies (Leonard et al., 2008; Benekareddy et al., 2011; 
Erhardt et al., 2011; Desbonnet et al., 2012; Mustafa et al., 2015; Bahi et al., 
2016; Knoll et al., 2016; Nieto et al., 2016). 
The CpGs lying within the target genes were selected from the meta-analysis 
results of the EWAS and FDR correction of 5% was applied for the number of 
CpGs included in the gene.  
 
 Disease Association Analysis  
To investigate a possible enrichment for specific pathways, I conducted a disease 
association analysis using Web Gestalt (Zhang et al., 2005; Wang et al., 2013), 
DAVID (Huang da et al., 2009a, b) and the R-package DOSE (Yu et al., 2015). 
Tested genes for a disease enrichment were annotated from CpG sites with P-
value < 0.001 in the meta-analysis results of the cases vs controls EWAS in the 
whole sample (Ngenes=312), in the female subset (Ngenes=428) and in the male 
subset (Ngenes=379). The analysis was background corrected for the Illumina 
HumanMethylation450 BeadChip array annotated genes. 
 
 DNA Methylation Age Calculation 
DNA methylation age was calculated from peripheral blood of patients and 
controls included in the MPIP Panic Cohort I (N=165) and II (N=300). DNA 
methylation-based age prediction was performed using the R code and statistical 
pipeline developed by Horvath (Horvath, 2013). This predictor was developed 
using 82 Illumina DNA methylation array datasets (n = 7,844) involving 51 healthy 
tissues and cell types (Horvath, 2013). The raw data were normalized using BMIQ 
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normalization method (Teschendorff et al., 2013) implemented in the Horvath 
DNA methylation-based age predictor R script (Horvath, 2013). I then tested 
whether epigenetic age acceleration (∆-Age), calculated by subtracting the actual 
chronological age from DNA methylation age (Horvath, 2013), was associated 
with 1) case-control status; 2) the presence/absence of agoraphobia in PD 
patients. Since DNA methylation age is calculated from raw beta values, technical 
batches identified for MPIP Panic Cohort I and II (96-well plate) were included as 
covariates in the linear regression model together with age, sex and cell counts 
(Houseman and Horvath cell counts, specifically: PlasmaBlast, 
CD8pCD28nCD45Ran, CD8.naive,  CD4T,  NK,  Mono, Gran).  
 
 MPIP Dexamethasone Treatment Study 
Methylation levels of cg07308824 were tested for association with gene 
expression levels of the HECA mRNA (ILMN_1770667) using a linear mixed 
effects model within the lme4 package (Bates et al., 2015). 
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4. Results 
 Identification of Hidden Confounders 
MPIP Panic Cohort I (as well as MPIP Panic Cohort II) went through the quality 
control (QC) steps described in the Materials and Methods section. This QC 
pipeline has been used successfully previously (Zannas et al., 2015; Emeny et al., 
2017), I was therefore expecting to see similar results as previous studies. 
Surprisingly, the result of our first analysis in the MPIP Panic Cohort I showed a 
high inflation of test statistic (Figure 6).  
 
 
Figure 6. QQ-plot of the first case-control EWAS in the MPIP Panic Cohort I. 
Expected vs Observed –log10(p) of the results  for the case-control comparison 
(linear model, N=187). Lambda indicates the genomic inflation factor and it is 
defined as the ratio of the median of the empirically observed distribution of the 
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test statistic to the expected median (thus quantifying the extent of the bulk 
inflation and the excess false positive rate). 
 
Considering the small sample size (N=187), this result was clearly not due to a 
real case-control difference, but rather to hidden confounders which were still 
there even after batch correction. To exclude that a technical problem occurred 
during the experiment, I performed the same case-control analysis in the other 
samples (N=609, 399 MDD patients, 210 controls) that were processed together, 
in the same batch, with the MPIP Panic Cohort I. The results in this case were not 
significant and the QQ-plot showed no inflation (Figure 7). This confirmed that 
the inflation present in the MPIP Panic Cohort I was not due to a technical 
problem, but rather to unknown confounders. 
To investigate the possible sources of variability in the data, I used the Surrogate 
Variable Analysis (SVA) (Leek and Storey, 2007) approach, which has the aim of 
detecting hidden variability in a given dataset while protecting for the phenotype 
of interest. I therefore calculated the surrogate variables (SVs) protecting for the 
case-control status; I then checked for the correlation with our known batches 
(Supplementary Figure 3) and corrected including them in the regression model 
(Figure 8). None of the tested models with the SVs included performed much 
better than the initial model batch corrected using Combat.  
I then tested whether the model that I were using, the linear model (which is the 
model of election for methylation analysis due to the distribution of the data), 
was not the appropriate one, and applied a logistic regression (glm, 
family=binomial). The latter is in general useful in predicting a binary outcome 
from a set of continuous predictor variables, but it did not perform better than 
the linear model in our analysis (Figure 9).  
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Figure 7. QQ-plot of the case-control EWAS results in the MDD cohort (N=609). 
Linear model of the case-control analysis. 
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Figure 8. QQ-plot of the first case-control EWAS in the MPIP Panic Cohort I with 
SVs included in the model. 
Linear model with the first five surrogate variables included as covariates. 
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Figure 9. QQ-plot of the first case-control EWAS in the MPIP Panic Cohort I with 
glm applied and SVs included in the model. 
Logistic regression with the first five surrogate variables included as covariates. 
 
 
For this reason, I went deeper into the phenotypic characterization and went 
back to the laboratory to get more information about the samples, e.g. DNA 
extraction method, storage information, collection date. I then performed again 
the analysis considering the additional information. Strikingly, I realized that the 
processed samples were stored differently: only a few DNA samples (N=21) 
included in the MPIP Panic Cohort I, all (except one) controls, were stored at -
20°C while the rest of the samples was stored at 4°C. I hypothesized that this 
could be the factor possibly introducing a strong bias in the case-control analysis. 
However, it was a confounder I could not detect when correlating the principal 
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components with the known batches, even after including the storage 
information (Figure 10). The principal component analysis (PCA) did not reveal 
any cluster neither considering all the samples that were processed together 
(MPIP Panic Cohort I-MDD, Figure 11) nor analysing the MPIP Panic Cohort I 
alone (Figure 12). I therefore considered these samples as biological outliers and 
excluded them from the analysis. The resulting QQ-plot, after repeating the 
analysis without the outlier samples, does not show an inflation anymore (Figure 
13), proving that the different storage conditions might have been the hidden 
confounder I was looking for. 
 
 
 
Figure 10. Correlation plot for the MPIP Panic Cohort I-MDD data (N=699) after 
normalization, before batch correction.  
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Figure 11. Principal Component Analysis in the MPIP Panic Cohort I-MDD data 
(N=699) before (left) and after (right) batch correction for the Storage variable 
(1= extracted DNA stored at -20 °C, 2= extracted DNA stored at 4 °C). 
 
 
 
 
 
  
 
 
 
 
 
Figure 12. Principal Component Analysis in the MPIP Panic Cohort I (N=187) 
before (left) and after (right) batch correction for the Storage variable (1= 
extracted DNA stored at 4 °C, 2= extracted DNA stored at -20 °C). 
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Figure 13. QQ-plot of the case-control EWAS in the MPIP Panic Cohort I without 
the outlier samples. 
 
 
 Epigenome-Wide Association Study (EWAS) 
Genome-wide associations were performed in the MPIP Panic Cohort I (discovery 
sample), combined as well as stratified by sex. While no association survived 
correction for multiple testing in the overall samples and the male subset, one 
genome-wide association, cg07308824, surviving FDR of 5% (p= 1.094 x 10-7, p-
adj=0.046) was observed in the female subset of the MPIP Panic Cohort I 
(discovery sample). QQ plots for each of the analyses are presented in Figure 13 
and Supplementary Figures 4-8. cg07308824 is located in the promoter of the 
HECA gene and was hypermethylated in female PD patients (N=49) compared to 
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controls (N=48). The association and the direction of the association could be 
replicated in the MPIP Panic Cohort II (replication sample, p=0.035) and yielded a 
combined p-value of 1.651 x 10-8 in the meta-analysis, that would again survive 
correction for multiple testing (p-adj=0.004) (Figure 14-15). 
 
 
 
 
 
 
 
 
 
Figure 14. Manhattan plot of the Panic Disorder EWAS in females (meta-
analysis results). The x-axis shows chromosomal position and the y-axis shows 
−log10(P). The red line represents the multiple test threshold (p < 1.09 × 10−7).  
 
 
 
 
 
Figure 15. Box plot of DNA methylation levels for the genome-wide significant 
CpG, in the MPIP Panic Cohort I (discovery, p-adj= 0.046) and MPIP Panic Cohort 
II (replication, p=0.035). 
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 Targeted Gene Analysis 
The targeted gene analysis (see Supplementary Table 1-15 for the complete list 
of genes tested) using the meta-analysis results, yielded in females one 
significant CpG each (surviving 5% FDR correction over the CpGs in the gene) in 
ADCYAP1 (PACAP) (p-adj=0.010) and HTR1A (p-adj=0.041) (Figure 16). The same 
analysis yielded one significant CpG in SGK1 (p-adj=0.035) (Figure 17) in the 
whole sample and in males in FHIT (p-adj=0.010) and two significant CpGs in 
HTR2A (p-adj=0.015 and p-adj=0.029) (Figure 18) (Table 4). Single nominal 
associations have been found in the genes ADCY1P1R1, BDNF, COMT, CRH, 
CRHR1, GAD1, OXTR and TMEM132D.  No differential methylation was detected 
for NPSR1 between cases and controls. 
 
 
Table 4. Targeted gene analysis results for the significant CpGs  
 
Sample Gene CpG P-adj  
Meta-analysis 
Whole  SGK1 cg00959636 0.035 
Males 
FHIT cg07351758 0.010 
HTR2A 
cg09361691 0.015 
cg06476131 0.029 
Females 
ADCYAP1 (PACAP) cg13940693 0.010 
HTR1A cg16280141 0.041 
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Figure 16. Box plots of DNA methylation levels for the significant CpGs in the 
gene-targeted analysis in the MPIP Panic Cohort I (discovery) and MPIP Panic 
Cohort II (replication) in females.  
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Figure 17. Box plots of DNA methylation levels for the significant CpGs in the 
gene-targeted analysis in the MPIP Panic Cohort I (discovery) and MPIP Panic 
Cohort II (replication) in the whole sample.  
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Figure 18. Box plots of DNA methylation levels for the significant CpGs in the 
gene-targeted analysis in the MPIP Panic Cohort I (discovery) and MPIP Panic 
Cohort II (replication) in males.  
 
 Functional Characterization of Significant Results 
To assess the functionality of the significant CpG methylation site, association of 
methylation levels with gene expression of the HECA mRNA was tested. 
Methylation at this CpG site was associated with mRNA expression of HECA 
(ILMN_1770667) both at baseline (p=0.046) and after induction by 
dexamethasone (p=0.029) (Figure 19). Gene expression was significantly altered 
in the sample following dexamethasone induction (p=8.78e-05) but not DNA 
methylation (p=0.796) (Figure 20), indicating that the significant association 
between gene expression and DNA methylation is specific and not due to 
dexamethasone.  
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Figure 19. Functional characterization of significant results.  
Scatterplot showing the association between DNA methylation (x-axis, beta 
values) and gene-expression (y-axis, VSN normalized array probe intensity) in an 
independent female sample at baseline (p=0.046) and after induction by 
dexamethasone (p=0.029). 
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Figure 20. Box plot of DNA methylation and gene expression levels in the MPIP 
dexamethasone treatment study. 
DNA methylation levels on the left (p=0.796) and gene expression levels on the 
right (p=8.78e-05) at baseline and after dexamethasone induction in the MPIP 
dexamethasone treatment study. 
 
 
 Functional Annotation of the HECA Locus 
I further investigated the functional relevance of cg07308824 in the UCSC 
Genome Browser (Kent et al., 2002), located in the intragenic and enhancer 
region of the Homo sapiens headcase homolog (Drosophila) (HECA) gene on 
Chromosome 6 (Figure 21). An overlap was observed between the location of 
cg07308824 probe and histone 3 lysine 27 acetylation (H3K27Ac) on 7 cell lines 
from ENCODE (Rosenbloom et al., 2013), suggesting that the sequence where 
the probe is located is functional (Creyghton et al., 2010). 
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Figure 21. Annotation of the genome-wide significant CpG located in the HECA 
gene. The top panel contains the HECA gene model, located on Chr 6. The other 
two panels show the genome-wide significant CpG and the CpG island where the 
CpG is located. The bottom panel shows the levels of enrichment of the H3K27Ac 
mark in the HECA gene. Data were obtained from UCSC Genome Browser and 
plotted using the R package Gviz (Hahne and Ivanek, 2016). 
 
 
 Disease Association Analysis  
After the characterization of the genome-wide significant hit, I also wanted to 
investigate whether genes annotated to the top CpGs (p-value < 0.001) were 
enriched for specific diseases, especially psychiatric disorder. For this purpose I 
ran a disease association analysis using two web tools (Web Gestalt and DAVID) 
(Zhang et al., 2005; Huang da et al., 2009a; Wang et al., 2015) and the R-package 
DOSE (Yu et al., 2015). As for the previous analysis, I first analysed the whole 
sample of the MPIP Panic Cohort I and MPIP Panic Cohort II and then I stratified 
by sex.  
Looking broadly at the enrichment found for all the diseases in all the tools used, 
there was no disease that was enriched in all the three tools (Table 5). 
Looking more closely at disease enrichment with a focus on psychiatric disorder, 
an enrichment could be found in the whole sample (bipolar disorder, p=1.9e-2; 
mental disorders, p=2.5e-2) and in females (response to antipsychotic treatment, 
p=5.3e-2; ADHD, p=9.5e-2) using DAVID (Huang da et al., 2009a, b) (Table 6). 
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Table 5. Disease association analysis (General overlap) 
The table shows disease association results overlapping between the different 
pathway analysis tools used. Genes included in the analysis were annotated from 
CpGs with P < 0.001 in the meta-analysis results of the cases vs controls EWAS. 
 
 
Table 6. Disease association analysis (Psychiatric disorders) 
The table shows disease association results for psychiatric disorders. Genes 
included in the analysis were annotated from CpGs with P < 0.001 in the meta-
analysis results of the cases vs controls EWAS. 
 
 
 Blood-Brain Correlation of the HECA Locus 
No significant correlations were found between cg07308824 methylation levels 
and four different brain regions (i.e. prefrontal cortex, superior temporal gyrus, 
Pathway tool Whole sample Males Females 
Disease 
association 
overlapping 
between tools 
Germ Cell and 
Embryonal 
Neoplasm, 
Amyotrophic 
Lateral Sclerosis, 
Mental Disorders 
Type 2 Diabetes, 
Carcinoma 
Muscular 
Disease 
Web Gestalt - p=0.12 
 
p=0.001 
DAVID p=2.2e-2,  p=3.6e-
2,  p=2.5e-2 
p=2.8e-2, p=7.6e-2 
 
- 
DOSE (R-package) p=0.150,  p=0.07,  
p=0.154 
- p=0.121 
Pathway tool Whole sample Males Females 
Disease 
association with 
psychiatric 
disorders 
Bipolar disorder, 
Mental Disorders  
 Response to 
antipsychotic 
treatment, ADHD  
Web Gestalt - - - 
DAVID p=1.9e-2, p=2.5e-2 -   p=5.3e-2,  
P=9.5e-2 
DOSE (R-package) - - - 
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entorhinal cortex and cerebellum) in a linear regression model (Hannon et al., 
2015) (Supplementary Figure 6). 
 
 DNA Methylation Age and Agoraphobia 
Psychological stress is an important risk factor for accelerated aging and aging-
related diseases, including cardiovascular disease, immune dysregulation, and 
late-life neuropsychiatric disorders. Stress-related psychiatric disorders, including 
anxiety, PTSD and major depression, are themselves a risk for such diseases 
(Danese et al., 2008; Vaccarino et al., 2013; Meneghetti et al., 2017). The 
molecular mechanisms that link psychological stress with accelerated aging and 
aging-related diseases remain largely unknown. It has already been reported that 
stressors can induce lasting changes in DNA methylation (Weaver et al., 2004; 
Klengel et al., 2013), therefore one plausible mechanism that can act as a 
mediator in this process is epigenetic regulation through DNA methylation.  
PD is a strong stressor for the people affected and so far no studies have been 
carried out to determine whether patients affected by PD also develop age 
acceleration.  I was interested in investigating whether age acceleration was 
present in PD patients compared to controls, and whether age acceleration could 
be detected in the most severe patients, specifically the ones affected by panic 
disorder with agoraphobia.  
I first compared the ∆-age in PD patients with healthy controls in the whole MPIP 
Panic Cohort I (N=165, p=0.980) and II (N=300, p=0.282) and found no significant 
differences. I then stratified for sex and found no significant results in males 
(MPIP Panic Cohort I: N=68, p=0.835; MPIP Panic Cohort II: N=95, p=0.467) as 
well as in females (MPIP Panic Cohort I: N=97, p=0.964; MPIP Panic Cohort II: 
N=204, p=0.402) (Figure 22-23). 
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Figure 22. Violin plots of ∆-age by control-case status in the MPIP Panic Cohort I 
sample (from the left: whole sample, males only, and females only). 
 
 
 
 
 
Figure 23. Violin plots of ∆-age by control-case status in the MPIP Panic Cohort 
II sample (from the left: whole sample, males only, and females only). 
 
 
Because it is known that the symptoms of panic disorder are stronger in 
presence of agoraphobia (American Psychiatric Association, 2013), I 
hypothesized that epigenetic age acceleration (∆-age) would be positively 
associated with patients with agoraphobia and not in patients without. I then 
therefore restricted the analysis to patients only. 
I performed a first analysis in each dataset (MPIP Panic Cohort I and II) overall 
and then stratified by sex. I could confirm our hypothesis in the MPIP Panic 
Cohort II, where the ∆-age was positively associated with agoraphobia in the 
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whole dataset (N=131, p=0.016) and the association was stronger if females 
were analysed separately (N=83, p=0.005). Results were not significant in males. 
No association between ∆-age and agoraphobia was detected in the MPIP Panic 
Cohort I (Figure 24-25). 
 
 
 
 
 
Figure 24. Violin plots of ∆-age by agoraphobia status in the MPIP Panic Cohort 
I sample (from the left: whole sample, males only, and females only). 
 
 
 
 
Figure 25. Violin plots of ∆-age by agoraphobia status in the MPIP Panic Cohort 
II sample (from the left: whole sample, males only, and females only). 
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5. Discussion 
Panic disorder is a multifactorial disorder where both genetic and environmental 
factors contribute to its onset. Susceptibility genes for PD have been reported by 
previous genetic studies (Erhardt et al., 2011; Erhardt et al., 2012) (Howe et al., 
2016) (Weber et al., 2016) (Gottschalk and Domschke, 2016), but the mechanism 
involved in the pathogenesis of PD still remains to be clarified. Epigenetics is 
considered to be a mediator of environmental stressors on the genome, DNA 
methylation in particular. In this study I investigated whether DNA methylation is 
involved in panic disorder analysing blood samples of medication-free patients 
and healthy controls. Our results suggest that sex-specific DNA methylation 
changes are occurring in panic disorder patients and not in healthy controls and 
that epigenetic age is accelerated in PD patients with agoraphobia compared to 
PD patients without. This is, to our knowledge, the first study of this kind on PD 
in the European population. 
 
 Hidden Confounders 
Our results on the MPIP Panic Cohort I show the crucial importance of a good 
randomization process and a good experimental design. Even if our study was 
accurately randomized with cases and controls matched for age and sex, and 
distributed accordingly in different plates and slides, there were other variables, 
i.e. DNA storage, that introduced a considerable bias in our first analysis. 
Therefore, this demonstrates that the more information can be taken into 
consideration about the samples, the less will be the confounders in the analysis 
of the generated data. Crucial would be to take into account all the possible 
confounders already in the pre-experimental phase, so that batch effects can be 
avoided already in the laboratory. It is indeed known that if strong batch effects 
are present, it is not possible to disentangle the confounder from the 
experimental question under study (e.g. in a case-control study, if cases are 
separated in different slides from controls), so it is impossible in that case to get 
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rid of the batch effect.  Therefore, the experiment has to be repeated with well-
randomized samples for it to be analysable. 
In my analysis, I was probably not able to eliminate the hidden confounders with 
the surrogate variable analysis (SVA) because I was protecting for the case-
control status and only one out of 21 samples stored at -20°C was a control while 
the others were cases. 
I also could not see these outliers in the principal component analysis (PCA) of all 
the samples processed together (MPIP Panic Cohort I-MDD), because the 
difference in the storage treatment was randomly distributed between cases and 
controls (Figure 11). Surprisingly, a cluster was not present even when the PCA 
was performed on the MPIP Panic Cohort I only (Figure 12). 
 
 EWAS 
Genome-wide association of whole blood DNA methylation with PD cases and 
matched controls identified a locus (cg07308824), which was hypermethylated in 
female PD patients compared to healthy controls. This locus was also associated 
with case-control status in females in another independent sample and results 
were further confirmed with a meta-analysis (N=301). No methylation 
differences were identified at genome-wide level in the whole sample. This is the 
first and biggest EWAS for PD in a population with European background. 
The methylation locus that I identified in females is located in the intragenic and 
enhancer region (Kent et al., 2002) of the Homo sapiens headcase homolog 
(Drosophila) (HECA) gene on Chromosome 6. The HECA gene is a cell cycle 
regulator and may play an important role in human cancers e.g. hepatocellular 
carcinoma (Wang et al., 2015); however, only a few publications about this gene 
are available to date. The potential functional relevance of cg07308824 was 
further investigated in the UCSC Genome Browser (Kent et al., 2002). An overlap 
was observed between the location of cg07308824 probe and histone 3 lysine 27 
acetylation (H3K27Ac) on 7 cell lines from ENCODE (Rosenbloom et al., 2013) 
(Figure 21). H3K27Ac was previously found near to active regulatory elements 
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suggesting that the sequence where the probe is located is functional (Creyghton 
et al., 2010). The HECA gene is expressed in brain at lower levels compared to 
blood (Supplementary Figure 9) but I could not see any correlation between the 
methylation levels of the significant CpG found in blood and brain, which could 
indicate that the relevance of these results might be limited to blood. No 
significant correlations were found between cg07308824 methylation levels and 
four different brain regions (i.e. prefrontal cortex, superior temporal gyrus, 
entorhinal cortex and cerebellum) in a linear regression model using a publicly 
available data set (Hannon et al., 2015)(Supplementary Figure 10). 
It is noteworthy considering that methylation levels of the identified locus 
showed a significant correlation with gene expression levels of the HECA gene in 
another independent female sample, which points to the functional relevance of 
the observed methylation change. The fact that the direction of the association is 
positive (higher gene expression correlated with higher methylation) may be 
explained by the intragenic location of the significant locus. It has indeed 
previously been shown (Wagner et al., 2014) that a positive correlation with 
gene expression is expected for CpG probes located in the body of the gene and 
a negative correlation is expected for CpG probes located close to a gene’s TSS. 
The authors also report that however this is only partially verified, with one-third 
of the latter type showing a positive correlation and nearly half of the former 
type showing a negative correlation.  
Notably, the significant changes in DNA methylation presented here are small 
(0.08%) but replicable.  This is in line with results from the recent small Japanese 
EWAS in PD (Shimada-Sugimoto et al., 2017), where 40 significant CpGs with 
overall low methylation differences have been detected. Sex-specific associations 
were not reported, most likely because of the small sample size. Furthermore, 
similar effect sizes were observed in other methylome studies of complex 
disorders e.g. rheumatoid arthritis (Liu et al., 2013), multiple sclerosis (Huynh et 
al., 2014), Alzheimer’s disease (Lunnon et al., 2014) and schizophrenia (Montano 
et al., 2016). The latter study is to date the largest case-control EWAS in the 
psychiatric field, with 689 schizophrenia patients and 645 controls included in 
the analysis. A bigger (N=1522) epigenome-wide association study on anxiety in a 
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population-based cohort was recently published, suggesting the involvement of 
the ASB1 gene in anxiety-related phenotypes (Emeny et al., 2017). 
As epidemiological studies clearly show the relevant contribution of the 
environment to the development of anxiety disorders (South et al., 2016; Torvik 
et al., 2016) and that these influences result in DNA methylation changes (Teh et 
al., 2014), a strategy including higher sample size and integrating specific 
environment-related factors (such as number or structure of life events) might 
be more successful to detect higher case-control methylation differences in PD.  
Female-specific DNA methylation changes in PD have been previously shown 
both in mice (Papale et al., 2016) and in humans. A female-specific association 
and/or correlation of negative life events with decreased overall methylation 
levels has been shown for GAD1 and MAOA (Domschke et al., 2012; Domschke et 
al., 2013). In contrast, female-specific effects in terms of increased methylation 
levels of promoter region were observed in the FOXP3 gene for PD (Prelog et al., 
2016). Sex-specific findings regarding the methylation pattern have been also 
detected in depression, which is highly comorbid with PD, and psychosis (Byrne 
et al., 2013; Melas et al., 2013). 
Interestingly, the disease association analysis shows enrichment for psychiatric 
disorders in the whole sample and in females, but not in males. 
However, one of the limitations of the study is the lower number of males 
compared to females, which is due to the higher prevalence of the disease in the 
latter. This might also explain why no significant results were found in the male 
subset but only in females. For this reason a bigger study with a higher number 
of subjects, with possibly the same ratio between males and females, is 
necessary in order to confirm the sex-specificity of our findings.  
Another limitation is that I could not correct for the smoking status of the 
subjects, due to lack of information. I verified though that our significant 
genome-wide hit was not one of the top-associated CpGs in the biggest EWAS for 
cigarette smoking (Joehanes et al., 2016).  
 
A targeted gene approach was subsequently applied, with the aim of 
investigating if genes previously associated with PD or anxiety-related 
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phenotypes are affected at the methylation level. Five of the genes I analysed, 
i.e. HTR1A, HTR2A, ADCYAP1 (PACAP), FHIT and SGK1 showed different 
methylation patterns in PD patients compared to controls. For these genes, the 
evidence for a correlation with anxiety disorders at the genetic level could be 
confirmed in our data at the epigenetic level. SGK1 (serum/glucocorticoid 
regulated kinase 1) is one of the key player in the mediation of fast and chronic 
stress response and, therefore, could be implicated in the transition of the 
environmental stress influences via methylation (Cattaneo and Riva, 2016). It 
seems to play a role in the expression of conditioned fear in the animal model 
(Knoll et al., 2016) and is one target of miRNAs in the glucocorticoid pathway 
affecting neurogenesis and leading to anxiogenic and depressiogenic behaviour 
in mice (Jin et al., 2016). Additional evidence from human studies point to the 
implication of this gene in the pathophysiology of traumatic stress, e.g. PTSD 
(Licznerski et al., 2015) and our results point to a possible involvement in PD as 
well. The second gene which is implicated in the stress response regulation is 
PACAP (Pituitary adenylate cyclase-activating polypeptide). Ressler et al. could 
demonstrate a female specific significant correlation of the PACAP38 peptide 
concentration in blood with PTSD symptoms and diagnosis (Dias and Ressler, 
2013).  In line with these previous findings, I could also demonstrate a female 
specific significant methylation difference in one locus between cases and 
controls, suggesting that this gene may play an important role in long-lasting 
stress dependent pathophysiology in PD or other anxiety disorders. Similarly, a 
female specific methylation difference could be shown for the gene HTR1A. This 
serotonin receptor is the most abundant of all serotonin receptors in the brain 
and HTR1A variants have been shown to be associated with depression and 
defensive behaviour in PD patients (Straube et al., 2014). So far, there is no 
evidence for sex specific implication of HTR1A gene in PD or other mental 
disorders. There are instead already previous studies showing an association of 
HTR2A and PD (Unschuld et al., 2007; Howe et al., 2016), and supporting 
evidence comes from our results in males. Similarly, variants in the gene FHIT 
(fragile histidine triad) were nominally associated in GWAS studies with anxiety 
(Luciano et al., 2012) and PD (Erhardt et al., 2011) and were not sex specific. In a 
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recent huge meta-analysis for broad depression phenotype, several variants in 
FHIT were among the most significant hits (Direk et al., 2016). However, there 
was no difference in the burden of depressive symptoms or depression diagnosis 
between the male and female group in our study, therefore, I cannot refer our 
finding to depression as bias. For HTR1A, HTR2A and FHIT, sex-specific effects 
presented here need to be replicated and elucidated in further studies.  
 
 DNA Methylation Age 
Another aim of the study was to determine the effect of PD on epigenetic aging, 
as measured with the epigenetic clock (Horvath, 2013). I found that in the MPIP 
Panic Cohort II there was an increased epigenetic age acceleration in PD patients 
with agoraphobia compared to patients without and that results are stronger if 
females are analysed separately. This might be explained by the higher severity 
of PD in presence of agoraphobia (American Psychiatric Association, 2013). The 
fact that the association is stronger in females is in line with the other results of 
this study, which so far pointed at each level of our analysis towards a sex-
specific mechanism that may underlie the onset and pathophysiology of panic 
disorder. The results could not be confirmed in the MPIP Panic Cohort I, where 
no significant differences could be found. I also investigated whether there was 
age acceleration in PD patients compared to controls, but results were not 
significant neither in the whole samples, nor in the sex-stratified analysis, in both 
MPIP Panic Cohort I and II. This might be explained by the heterogeneity of the 
samples in terms of age. It was showed by Zannas et al. that the effect of 
personal life stress on ∆-age is stronger in older as compared to younger people 
(Zannas et al., 2015). This suggests that the effects in our study, if present, might 
be diluted by the age-range.  
To overcome the problem of the precision of the prediction of DNA methylation 
age, other predictors optimized for a different age-range have been developed. 
The Horvath age predictor was developed from primarily adult samples and has 
been used to accurately predict chronological age in children and adults 
(Horvath, 2013). It is known however that a prediction model is, in general, 
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weakest at the extremes of the distribution. Knight et al. therefore designed a 
predictor optimized to accurately estimate gestational age (GA) that can also be 
informative of developmental stage (Knight et al., 2016).  
 
 Limitations of the Study 
Psychiatric disorders are complex and heterogeneous disorders that bear the 
disadvantage that the primary organ affected, the brain, is usually not available. 
On the other hand, the use of post-mortem brain tissue samples, while 
informative, has also limits and  cannot capture the fluid state of the epigenome 
in vivo (Tylee et al., 2013). For this reason surrogate tissues that are more easily 
accessible, e.g. blood, have been often used as a potential proxy and source of 
biomarkers that may reflect the state of illness in the brain (Tylee et al., 2013). 
The limitations of the latter are certainly that their results only allow for indirect 
conclusions about the associated biological processes in living brain tissue. 
Walton et al. used a within-subject design to investigate the blood-brain 
correspondence of DNA methylation and found that most DNA methylation 
markers in peripheral blood do not reliably predict brain DNA methylation status 
(Walton et al., 2016). However, a subset of peripheral data may proxy 
methylation status of brain tissue. Therefore, the authors suggest that restricting 
the analysis to these markers can identify meaningful epigenetic differences in 
brain disorders (Walton et al., 2016). 
Horvath et al. investigated the effects of age on genome-wide methylation levels 
in leukocytes and brain tissue samples (frontal and temporal cortex, pons, and 
cerebellum). According to their review (Horvath et al., 2012), a number of 
factors, such as the location of the specific CpG site (island, non-island, proximity 
to promoter) and the participation of the gene in developmentally regulated 
gene expression programs influence age-related changes in methylation (Tylee et 
al., 2013). Their results moreover indicated a high correlation between blood and 
brain methylation levels (approximate r=0.9); the effects of age on methylation 
levels were also moderately conserved (approximate r=0.3). Their conclusion was 
that the blood-brain methylome is more closely correlated than blood-brain gene 
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expression values as detected by microarray (approximate r=0.6) (Tylee et al., 
2013). In the same direction, Kaminsky et al. observed a significant positive 
relationship between age and methylation levels at specific CpG sites in both 
blood and brain samples (Kaminsky et al., 2012). 
A number of studies (Kronfol and Remick, 2000; Felger and Lotrich, 2013; Emeny 
et al., 2017) have implicated immune changes as one possible contributor to the 
pathophysiology of psychiatric disorders, therefore peripheral blood may give 
direct mechanistic insight into the brain (Klengel and Binder, 2015). 
In summary, not all the findings deriving from peripheral blood reflect what is 
happening in the brain, but a close correspondence may indeed exist for many 
genes. The results presented in this thesis should be therefore considered with 
caution.
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6. Conclusions and Outlook 
The work described in this thesis examines epigenome-wide differences in 
peripheral blood for PD patients and suggests that possible sex-specific 
methylation changes are occurring, specifically in the HECA gene.  Moreover, 
epigenetic age seems to be accelerated in PD patients with agoraphobia 
compared to patients without, with effects being stronger in females. 
However, these results have to be considered preliminary and their validity 
might be limited to peripheral blood. Therefore, more studies with bigger sample 
sizes and possibly in different biological tissues have to be performed to gain 
more insights into the role of DNA methylation and the HECA gene in PD as well 
as the sex-specificity. To address these questions, a bigger replication sample 
should also include an equal number of males and females. 
As a second layer of analysis, epigenetic age acceleration should be measured in 
other cohorts of PD patients with and without agoraphobia to confirm our 
findings of age acceleration occurring in PD patients with agoraphobia. 
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7. Supplementary Material 
Supplementary Tables 1-15.  Targeted gene analysis  
List of all the CpGs tested for every target gene. Beta and P-values refer to the 
EWAS meta-analysis results in the whole sample and stratified by sex.  
 
ADCYAP1 (PACAP) 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00067606 -0.0504 0.4317 0.949447 -0.2272 0.03499 0.28668 0.0449 0.5866 0.900692 
cg04105966 -0.0066 0.878 0.949447 -0.0781 0.3986 0.8712 -0.0082 0.8722 0.9198 
cg06372303 0.0034 0.9629 0.9629 -0.0466 0.7303 0.8712 0.1528 0.1048 0.4062 
cg07211875 0.0098 0.8622 0.949447 0.0276 0.7744 0.8712 0.0425 0.5534 0.900692 
cg07376535 0.045 0.496 0.949447 -0.0348 0.7729 0.8712 0.1765 0.03384 0.24714 
cg07788286 -0.0116 0.8967 0.949447 -0.3214 0.06718 0.30231 -0.028 0.798 0.9198 
cg10384245 0.045 0.3765 0.949447 0.0368 0.6656 0.8712 0.0847 0.2008 0.4062 
cg11402363 0.0815 0.2328 0.949447 0.0413 0.7456 0.8712 0.0261 0.7596 0.9198 
cg11771234 0.0213 0.7908 0.949447 0.2461 0.0894 0.32184 -0.0479 0.6312 0.900692 
cg11859607 -0.0491 0.352 0.949447 -0.0317 0.7281 0.8712 0.0068 0.9198 0.9198 
cg13940693 0.0084 0.8805 0.949447 -0.1812 0.03518 0.28668 0.2438 0.000593 0.010674 
cg14200170 -0.127 0.03223 0.58014 0.0071 0.9451 0.9481 -0.0347 0.6505 0.900692 
cg14479567 0.0301 0.7072 0.949447 -0.0782 0.5644 0.8712 0.136 0.1837 0.4062 
cg14489474 -0.0192 0.8281 0.949447 -0.0642 0.6738 0.8712 -0.2295 0.04119 0.24714 
cg14908653 -0.0248 0.7178 0.949447 -0.2592 0.04778 0.28668 -0.0192 0.8178 0.9198 
cg17439660 0.0661 0.3505 0.949447 0.0834 0.4905 0.8712 0.1198 0.2031 0.4062 
cg21331088 -0.0123 0.7441 0.949447 0.0675 0.2967 0.8712 -0.0696 0.1557 0.4062 
cg22374233 -0.0528 0.3309 0.949447 -0.006 0.9481 0.9481 0.0956 0.1964 0.4062 
 
ADCYAP1R1 (PACAP receptor) 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg01556466 -0.1996 0.03595 0.670383 -0.1541 0.3582 0.618709 -0.1724 0.1913 0.841067 
cg02418899 -0.0239 0.7897 0.9983 0.0307 0.8359 0.9329 0.1 0.3876 0.841067 
cg02846790 0.0589 0.3935 0.830722 -0.0105 0.9329 0.9329 -0.0195 0.8211 0.976041 
cg03447880 -0.0453 0.322 0.830722 -0.0539 0.5013 0.793725 -0.0366 0.5312 0.841067 
cg04879561 -0.0016 0.9859 0.9983 -0.1654 0.2648 0.54188 0.0909 0.4223 0.841067 
cg10000602 -0.1618 0.1722 0.670383 -0.4688 0.012 0.228 -0.0014 0.9929 0.9951 
cg11218385 -0.0547 0.3655 0.830722 -0.0556 0.6069 0.887008 -0.0797 0.2933 0.841067 
cg12140543 0.1192 0.2112 0.670383 0.0215 0.8924 0.9329 0.068 0.584 0.853538 
cg13886135 0.0369 0.693 0.9983 -0.3401 0.04424 0.366637 -0.089 0.4496 0.841067 
cg14785679 0.0227 0.7944 0.9983 -0.2577 0.05789 0.366637 -0.0187 0.8704 0.976041 
cg16621855 0.0237 0.6881 0.9983 -0.0185 0.853 0.9329 0.012 0.8733 0.976041 
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cg17822807 0.0309 0.6739 0.9983 0.2252 0.09804 0.406283 0.0645 0.4884 0.841067 
cg18421840 2.00E-04 0.9983 0.9983 -0.1469 0.2852 0.54188 6.00E-04 0.9951 0.9951 
cg19317517 -0.1125 0.1589 0.670383 -0.2136 0.1283 0.406283 0.077 0.4528 0.841067 
cg21619594 -0.0942 0.2117 0.670383 -0.1646 0.1855 0.440563 0.1132 0.2545 0.841067 
cg21844005 -0.0281 0.7024 0.9983 0.1969 0.1213 0.406283 0.0733 0.4511 0.841067 
cg22963629 -0.0108 0.8824 0.9983 -0.1733 0.1785 0.440563 0.0236 0.804 0.976041 
cg24384519 -0.0066 0.9329 0.9983 -0.0557 0.6671 0.90535 0.2632 0.0117 0.2223 
cg25195987 0.1254 0.1718 0.670383 -0.0373 0.8174 0.9329 0.1264 0.2964 0.841067 
 
BDNF 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00298481 -0.1265 0.285 0.855536 0.1718 0.3485 0.7675 0.097 0.5367 0.934125 
cg01418645 0.078 0.3517 0.855536 -0.0977 0.4971 0.771184 0.1157 0.2892 0.934125 
cg05189570 0.0183 0.8676 0.915208 -0.107 0.573 0.771184 0.08 0.5722 0.934125 
cg06025631 0.0686 0.4779 0.855536 0.2301 0.1765 0.735417 0.0388 0.7473 0.934125 
cg06260077 -0.0075 0.938 0.938 0.0983 0.5861 0.771184 -0.0024 0.9835 0.9835 
cg06979684 -0.0738 0.3139 0.855536 -0.2008 0.1077 0.6975 -0.1534 0.09701 0.934125 
cg07159484 0.0165 0.7782 0.915208 0.1106 0.2676 0.7675 0.1126 0.1304 0.934125 
cg07238832 -0.0485 0.6191 0.915208 -0.2511 0.134 0.6975 0.0158 0.8999 0.940833 
cg08388004 0.1013 0.2613 0.855536 -0.1435 0.3347 0.7675 0.1149 0.3399 0.934125 
cg09492354 -0.0477 0.6261 0.915208 0.0184 0.9114 0.96625 -0.1694 0.1906 0.934125 
cg10558494 -0.0967 0.2255 0.855536 -0.2112 0.1395 0.6975 0.2338 0.01978 0.4945 
cg14291693 -0.0895 0.3045 0.855536 -0.0999 0.4771 0.771184 0.0543 0.6402 0.934125 
cg15014679 -0.0583 0.4299 0.855536 0.0429 0.7265 0.864881 -0.0516 0.5985 0.934125 
cg15313332 0.0617 0.4583 0.855536 0.0624 0.6666 0.83325 0.0605 0.5703 0.934125 
cg18117895 -0.0904 0.2966 0.855536 -0.1263 0.4298 0.7675 -0.0523 0.6224 0.934125 
cg18354203 -0.0276 0.6872 0.915208 -0.1422 0.2245 0.7675 -0.033 0.7032 0.934125 
cg18595174 -0.0445 0.5585 0.915208 -0.0171 0.8961 0.96625 -0.0218 0.8232 0.940833 
cg20108357 0.0865 0.2285 0.855536 -0.1808 0.1364 0.6975 0.0169 0.8554 0.940833 
cg20954537 -0.0354 0.7109 0.915208 0.0945 0.5578 0.771184 0.1082 0.3856 0.934125 
cg23426002 -0.0692 0.4791 0.855536 -0.1361 0.4151 0.7675 -0.0407 0.7343 0.934125 
cg23619332 -0.0184 0.8786 0.915208 -0.0191 0.9276 0.96625 0.0976 0.5288 0.934125 
cg23947039 0.1282 0.01451 0.36275 0.221 0.03315 0.6975 0.0266 0.6894 0.934125 
cg25962210 0.0639 0.4228 0.855536 0.1512 0.3036 0.7675 0.0548 0.5954 0.934125 
cg26057780 -0.0133 0.864 0.915208 -0.0024 0.987 0.987 -0.0114 0.9032 0.940833 
cg27193031 -0.0243 0.7932 0.915208 -0.1441 0.3757 0.7675 0.0579 0.6272 0.934125 
 
COMT 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00107488 0.0065 0.9401 0.9802 0.1968 0.1889 0.611578 -0.1524 0.1805 0.736447 
cg00465975 -0.0069 0.9244 0.9802 0.07 0.5822 0.860119 -0.0169 0.8565 0.8834 
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cg03205258 -0.005 0.8893 0.9802 -0.0318 0.5999 0.860119 -0.0068 0.8834 0.8834 
cg03724721 -0.0253 0.7949 0.9802 0.0681 0.7012 0.860119 0.0843 0.478 0.736447 
cg04856117 -2.00E-04 0.9983 0.9983 -0.1824 0.1728 0.611578 0.0153 0.8826 0.8834 
cg06045576 0.1157 0.204 0.935894 0.0784 0.6336 0.860119 -0.2391 0.03039 0.464 
cg06346307 0.0518 0.5645 0.935894 -0.4143 0.004372 0.126788 0.0222 0.8528 0.8834 
cg06787004 0.108 0.2796 0.935894 0.0729 0.6573 0.860119 0.1988 0.1327 0.736447 
cg06860277 0.0781 0.4868 0.935894 0.0689 0.7224 0.860119 0.0402 0.7786 0.8834 
cg07579946 0.0504 0.5809 0.935894 -0.0743 0.6332 0.860119 0.1277 0.284 0.736447 
cg08289189 -0.0089 0.8944 0.9802 -0.0694 0.5459 0.860119 0.0445 0.6038 0.833813 
cg08730070 0.1632 0.04414 0.320015 0.2221 0.1532 0.611578 0.0999 0.3163 0.736447 
cg09926649 -0.0831 0.2905 0.935894 -0.169 0.1792 0.611578 -0.0159 0.8779 0.8834 
cg10122187 0.0221 0.7038 0.971914 -0.0258 0.7844 0.860119 -0.0853 0.2765 0.736447 
cg10253022 0.0793 0.3768 0.935894 -0.1159 0.4682 0.860119 0.0839 0.4529 0.736447 
cg11361387 -0.0887 0.1439 0.83462 -0.1254 0.1898 0.611578 0.0718 0.3931 0.736447 
cg12728623 0.0632 0.5121 0.935894 0.1581 0.3218 0.777683 -0.0564 0.6594 0.833813 
cg13175282 0.2176 0.01142 0.320015 0.0379 0.8008 0.860119 0.1246 0.2558 0.736447 
cg16834011 0.1582 0.04337 0.320015 0.0384 0.7707 0.860119 0.2201 0.032 0.464 
cg18731680 -0.0442 0.4924 0.935894 0.0352 0.7272 0.860119 -0.0702 0.4219 0.736447 
cg18773129 0.0376 0.6234 0.951505 0.0064 0.9598 0.9598 0.0447 0.6613 0.833813 
cg19930203 -0.162 0.0234 0.320015 -0.0174 0.8799 0.911325 0.0444 0.6474 0.833813 
cg20709110 -0.0033 0.9464 0.9802 0.0964 0.244 0.7076 -0.0699 0.2569 0.736447 
cg21905167 0.0423 0.5738 0.935894 -0.0626 0.6084 0.860119 -0.1944 0.05099 0.492903 
cg21919834 0.0318 0.6771 0.971914 -0.2054 0.1658 0.611578 0.1107 0.233 0.736447 
cg22546130 -0.0231 0.7766 0.9802 -0.3316 0.01465 0.212425 0.186 0.07032 0.50982 
cg23601416 0.0841 0.32 0.935894 -0.147 0.3039 0.777683 0.0963 0.3826 0.736447 
cg25836061 -0.0451 0.4905 0.935894 -0.1444 0.1616 0.611578 0.0652 0.4825 0.736447 
cg27521571 0.0523 0.4265 0.935894 -0.05 0.6345 0.860119 0.0763 0.3681 0.736447 
 
CRH 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00603617 0.1035 0.2519 0.431829 0.0085 0.958 0.958 -0.0175 0.8787 0.8787 
cg03405789 -0.1706 0.02053 0.10688 0.0112 0.936 0.958 -0.1043 0.2391 0.35865 
cg08215831 0.07 0.1503 0.3006 -0.0141 0.8841 0.958 0.1449 0.01404 0.08424 
cg15971888 -0.0269 0.7758 0.7758 -0.1252 0.497 0.958 -0.0546 0.6326 0.75912 
cg17305181 -0.0466 0.3381 0.4508 -0.0711 0.4154 0.958 0.0911 0.1394 0.248914 
cg18640030 0.1051 0.02672 0.10688 0.0258 0.7515 0.958 0.089 0.1452 0.248914 
cg19035496 0.0306 0.5702 0.68424 0.2023 0.04534 0.54408 0.0972 0.1404 0.248914 
cg20329958 -0.1223 0.1017 0.24408 -0.1603 0.1738 0.958 -0.1859 0.05638 0.18723 
cg21240762 0.1022 0.3175 0.4508 0.1002 0.5859 0.958 0.029 0.8195 0.8787 
cg21878188 0.048 0.6343 0.691964 -0.1515 0.3789 0.958 0.2398 0.06241 0.18723 
cg23027580 0.2001 0.009545 0.10688 0.0882 0.5185 0.958 0.2669 0.005015 0.06018 
cg23409074 0.0995 0.0688 0.2064 -0.0484 0.6452 0.958 0.0608 0.3636 0.4848 
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CRHR1 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00022871 0.0498 0.637 0.975 -0.0833 0.63 0.987553 0.0666 0.624 0.763688 
cg00025823 0.0099 0.8965 0.975 0.0873 0.5061 0.987553 0.0659 0.5093 0.730414 
cg04856689 -0.0952 0.1 0.823175 -0.156 0.128 0.608 -0.0457 0.5304 0.730414 
cg07778819 -0.0903 0.1733 0.823175 0.0083 0.9416 0.9922 0.0538 0.5382 0.730414 
cg11338426 -0.172 0.1522 0.823175 -0.3406 0.1064 0.608 -0.0979 0.506 0.730414 
cg11731737 0.0045 0.9309 0.975 -0.0199 0.8275 0.987553 0.0164 0.8008 0.845289 
cg13521908 -0.1154 0.2961 0.892156 0.0257 0.8836 0.987553 -0.2714 0.0674 0.730414 
cg13947929 -0.054 0.4226 0.892156 -0.0012 0.9922 0.9922 0.0683 0.4239 0.730414 
cg15607306 0.066 0.4151 0.892156 0.0319 0.8166 0.987553 0.0015 0.9889 0.9889 
cg16642545 0.0608 0.4768 0.90592 -0.1068 0.4444 0.987553 -0.1061 0.3516 0.730414 
cg16830379 -0.0824 0.3382 0.892156 -0.2499 0.08074 0.608 -0.0785 0.4758 0.730414 
cg18534039 -0.0078 0.9323 0.975 -0.0653 0.7171 0.987553 0.0503 0.6598 0.763688 
cg24063856 -0.0368 0.5671 0.975 -0.0778 0.5036 0.987553 -0.0333 0.6833 0.763688 
cg24353392 0.003 0.975 0.975 -0.1281 0.4467 0.987553 0.1821 0.1323 0.730414 
cg24394631 0.0156 0.7464 0.975 -0.0667 0.4246 0.987553 0.0592 0.3558 0.730414 
cg26656751 -0.0145 0.7419 0.975 -0.1694 0.0119 0.2261 -0.0373 0.5311 0.730414 
cg27410679 0.0867 0.3052 0.892156 0.0731 0.5889 0.987553 -0.0864 0.4364 0.730414 
cg27503360 -0.1991 0.05718 0.823175 -0.0279 0.8809 0.987553 -0.18 0.1794 0.730414 
cg27551605 -0.0097 0.8815 0.975 0.0193 0.8578 0.987553 0.1369 0.1014 0.730414 
 
FHIT 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00071984 0.1004 0.174 0.72501 -0.02 0.8903 0.9912 0.094 0.2899 0.9447 
cg00506250 -0.0727 0.5265 0.982695 -0.1749 0.3757 0.9912 -0.003 0.9838 0.9951 
cg00658590 0.1067 0.2702 0.820393 0.0401 0.8001 0.9912 0.0962 0.436 0.989733 
cg00721771 0.0645 0.3802 0.982695 0.0014 0.9912 0.9912 0.1003 0.31 0.9447 
cg01556706 0.0182 0.7415 0.982695 -0.146 0.1233 0.80145 -0.0193 0.7822 0.9951 
cg02923224 0.0343 0.6361 0.982695 -0.0808 0.5541 0.9912 0.046 0.613 0.9951 
cg03060986 0.2573 0.002328 0.090792 -0.1763 0.2237 0.9912 0.1497 0.1831 0.826367 
cg03319184 -0.0027 0.9677 0.9892 0.0017 0.9877 0.9912 -0.0384 0.6607 0.9951 
cg03610148 0.1937 0.05035 0.63102 -0.0018 0.991 0.9912 0.2637 0.04792 0.6357 
cg04216480 0.0827 0.2945 0.820393 -0.026 0.8453 0.9912 0.1799 0.08276 0.6357 
cg04383442 0.1798 0.05617 0.63102 -0.148 0.3314 0.9912 0.0331 0.7881 0.9951 
cg04835638 0.1208 0.1859 0.72501 0.0535 0.7414 0.9912 0.2417 0.0362 0.6357 
cg05645292 0.1099 0.1488 0.72501 0.0926 0.4818 0.9912 -0.0221 0.8179 0.9951 
cg05709770 -0.1124 0.1202 0.72501 -0.2657 0.03914 0.305292 0.01 0.9124 0.9951 
cg07351758 -0.0112 0.9048 0.982695 -0.6192 0.000274 0.010694 0.1809 0.1136 0.6357 
cg08223225 -0.0015 0.9892 0.9892 -0.0515 0.8039 0.9912 0.2412 0.07833 0.6357 
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cg10763247 0.1066 0.2341 0.820393 -0.1009 0.4984 0.9912 0.0111 0.9248 0.9951 
cg11815980 -0.0256 0.7883 0.982695 -0.0703 0.6783 0.9912 0.0922 0.4568 0.989733 
cg13679804 0.0153 0.7701 0.982695 0.0627 0.4471 0.9912 0.0545 0.456 0.989733 
cg13745692 0.0543 0.5126 0.982695 0.0468 0.7276 0.9912 0.0724 0.5194 0.9951 
cg14147855 -0.0305 0.7321 0.982695 -0.0088 0.9542 0.9912 7.00E-04 0.9951 0.9951 
cg15135842 0.0198 0.8306 0.982695 -0.1549 0.3627 0.9912 -0.0535 0.6371 0.9951 
cg15238012 -0.0655 0.4165 0.982695 -0.1304 0.3482 0.9912 0.0924 0.3613 0.989733 
cg15970800 0.0303 0.7785 0.982695 0.0448 0.8196 0.9912 0.02 0.8825 0.9951 
cg16806041 -0.0484 0.5667 0.982695 -0.0395 0.7892 0.9912 0.0181 0.8687 0.9951 
cg17087356 0.1739 0.06472 0.63102 0.1753 0.2861 0.9912 0.0325 0.7865 0.9951 
cg17894779 0.0977 0.2918 0.820393 -0.0815 0.6151 0.9912 0.1838 0.1141 0.6357 
cg19282443 0.1679 0.1161 0.72501 0.0901 0.6283 0.9912 -0.0136 0.92 0.9951 
cg19729536 -0.0066 0.9323 0.982695 -0.0545 0.6815 0.9912 -0.0207 0.8386 0.9951 
cg20366397 0.0305 0.7811 0.982695 -0.1105 0.5522 0.9912 0.0604 0.6695 0.9951 
cg20517149 -0.0577 0.4933 0.982695 -0.3129 0.02887 0.305292 -0.0653 0.5301 0.9951 
cg22380007 0.0081 0.8393 0.982695 -0.2264 0.00176 0.03432 0.0521 0.2877 0.9447 
cg22533480 -0.0134 0.8636 0.982695 0.0472 0.7022 0.9912 -0.181 0.07068 0.6357 
cg23222057 -0.0064 0.9299 0.982695 -0.2589 0.03471 0.305292 -0.0534 0.5666 0.9951 
cg23737061 -0.0633 0.4357 0.982695 -0.09 0.4774 0.9912 -0.0899 0.4052 0.989733 
cg25724751 0.0331 0.6593 0.982695 -0.1619 0.1836 0.9912 -0.0011 0.9913 0.9951 
cg25921543 0.044 0.6272 0.982695 0.0909 0.5333 0.9912 0.1528 0.1907 0.826367 
cg26358659 0.0211 0.8371 0.982695 -0.2083 0.247 0.9912 0.0218 0.8667 0.9951 
cg27254860 0.105 0.1714 0.72501 0.0114 0.933 0.9912 0.0976 0.3149 0.9447 
 
FKBP5 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00140191 -0.0095 0.9156 0.9156 -0.076 0.6362 0.956114 0.0457 0.682 0.909333 
cg00862770 -0.0144 0.875 0.9156 -0.2893 0.05151 0.41208 0.0807 0.496 0.878109 
cg02665568 0.0397 0.6025 0.9156 -0.0746 0.5369 0.956114 -0.0551 0.5872 0.878109 
cg03546163 0.0154 0.8468 0.9156 -0.0303 0.8366 0.956114 0.0743 0.4578 0.878109 
cg06087101 -0.1129 0.09849 0.7904 -0.1248 0.3068 0.867733 0.0451 0.6037 0.878109 
cg07061368 -0.0127 0.8722 0.9156 -0.0317 0.8151 0.956114 -0.0798 0.4227 0.878109 
cg07633853 -0.037 0.6138 0.9156 -0.2626 0.0283 0.41208 -0.172 0.07264 0.878109 
cg08586216 -0.0167 0.8784 0.9156 0.1918 0.3254 0.867733 0.0043 0.975 0.975 
cg10300814 0.0487 0.6327 0.9156 -0.0059 0.9747 0.9852 0.0242 0.8557 0.94528 
cg10913456 -0.0824 0.2729 0.9156 -0.1859 0.1979 0.867733 -0.0489 0.5884 0.878109 
cg14284211 -0.0296 0.5765 0.9156 0.0247 0.7918 0.956114 0.0098 0.8862 0.94528 
cg14642437 0.0135 0.8462 0.9156 -0.0527 0.6653 0.956114 0.1002 0.2648 0.878109 
cg16052510 0.0568 0.3671 0.9156 -0.0764 0.4941 0.956114 0.0474 0.5502 0.878109 
cg17085721 0.0286 0.736 0.9156 0.0026 0.9852 0.9852 0.0953 0.3893 0.878109 
cg18726036 0.112 0.09913 0.7904 -0.0578 0.6615 0.956114 -0.0273 0.7471 0.919508 
cg19014730 0.1435 0.1482 0.7904 -0.2024 0.2339 0.867733 0.1177 0.3461 0.878109 
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GAD1 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00224929 -0.1151 0.2565 0.582955 -0.0017 0.9926 0.9926 0.089 0.4797 0.9953 
cg00729049 -0.0639 0.3315 0.6375 -0.0601 0.5836 0.892059 -0.0209 0.7982 0.9953 
cg01089249 0.0021 0.9756 0.9756 -0.3051 0.006905 0.172625 0.0619 0.4815 0.9953 
cg01089319 -0.0659 0.1748 0.517222 -0.1306 0.1276 0.556591 -0.0415 0.4882 0.9953 
cg01763173 0.1152 0.144 0.517222 -0.1679 0.2026 0.556591 0.0336 0.7518 0.9953 
cg02723395 0.0045 0.9298 0.968542 -0.1428 0.111 0.556591 0.0019 0.9766 0.9953 
cg04105250 0.0493 0.4382 0.695313 -0.0047 0.9669 0.9926 0.1051 0.1991 0.9953 
cg07420274 -0.0169 0.7377 0.922125 -0.0281 0.7614 0.964643 5.00E-04 0.9942 0.9953 
cg08863440 -0.1331 0.006858 0.17145 0.0072 0.9323 0.9926 -0.006 0.9258 0.9953 
cg09144707 0.0111 0.8725 0.968542 0.0548 0.6711 0.932083 0.0955 0.2618 0.9953 
cg11281641 0.0324 0.6359 0.922125 -0.0311 0.8103 0.964643 -0.0278 0.7345 0.9953 
cg11348701 -0.1768 0.0494 0.30875 -0.0967 0.5006 0.892059 -0.0689 0.5692 0.9953 
cg11582100 0.0139 0.8867 0.968542 -0.0867 0.6066 0.892059 0.0358 0.7731 0.9953 
cg14005211 -0.0698 0.04549 0.30875 -0.12 0.0499 0.425417 -0.0434 0.3229 0.9953 
cg14486905 -0.0578 0.1862 0.517222 -0.0986 0.1816 0.556591 0.064 0.252 0.9953 
cg14914809 -0.0296 0.7286 0.922125 -0.184 0.2449 0.556591 -0.0326 0.752 0.9953 
cg15126544 0.0712 0.1489 0.517222 -0.1252 0.1661 0.556591 0.1095 0.06797 0.849625 
cg15306595 -0.2275 0.03319 0.30875 -0.117 0.5319 0.892059 0.0297 0.8302 0.9953 
cg15753746 -0.1095 0.1203 0.517222 0.1533 0.167 0.556591 6.00E-04 0.9953 0.9953 
cg16911423 0.089 0.445 0.695313 -0.0499 0.8094 0.964643 0.0822 0.5667 0.9953 
cg19009018 0.0927 0.2564 0.582955 -0.1659 0.2248 0.556591 0.0544 0.6077 0.9953 
cg19538089 -0.0079 0.9169 0.968542 -0.0214 0.8637 0.981477 0.0853 0.3836 0.9953 
cg19846314 -0.0378 0.3886 0.693929 0.1399 0.05105 0.425417 -0.0109 0.8495 0.9953 
cg21535772 -0.0975 0.3259 0.6375 -0.0975 0.5732 0.892059 0.0456 0.7215 0.9953 
cg26391350 -0.0384 0.6655 0.922125 -0.0802 0.5764 0.892059 0.23 0.05303 0.849625 
 
HTR1A 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg01020744 0.0106 0.8343 0.903825 0.0908 0.3018 0.594425 0.0226 0.7247 0.817267 
cg02266732 -0.0476 0.3816 0.674818 0.0273 0.792 0.812 0.0213 0.7544 0.817267 
cg04694812 -0.1448 0.01779 0.23127 -0.1747 0.07498 0.324913 0.0712 0.4038 0.61061 
cg04799838 0.1181 0.1346 0.660833 0.0964 0.4784 0.616318 0.138 0.1705 0.484714 
cg07839533 -0.0996 0.1525 0.660833 -0.1644 0.1596 0.5187 -0.1075 0.2272 0.484714 
cg08259925 0.0332 0.571 0.674818 0.068 0.5215 0.616318 0.0904 0.2423 0.484714 
cg09698471 0.0487 0.477 0.674818 -0.2473 0.03323 0.324913 -0.0121 0.8856 0.8856 
cg10588470 0.0412 0.3416 0.674818 0.1407 0.06787 0.324913 0.0609 0.261 0.484714 
cg13666507 -0.052 0.3586 0.674818 -0.0714 0.4872 0.616318 0.1212 0.09676 0.484714 
cg15092168 -0.0382 0.521 0.674818 0.0844 0.3658 0.594425 -0.0968 0.2391 0.484714 
cg16280141 -0.0454 0.4468 0.674818 -0.1288 0.2331 0.594425 0.2164 0.003174 0.041262 
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cg23448729 0.0521 0.3248 0.674818 0.0914 0.3227 0.594425 -0.0507 0.4421 0.61061 
cg27615388 0.0017 0.9608 0.9608 -0.0139 0.812 0.812 0.0314 0.4697 0.61061 
 
HTR2A 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00308665 0.0488 0.4868 0.9857 -0.0733 0.5726 0.68712 -0.0276 0.7543 0.9396 
cg02250787 -0.0416 0.5508 0.9857 -0.2273 0.07555 0.210432 0.0146 0.8669 0.9396 
cg06476131 -0.013 0.8378 0.9857 -0.316 0.004871 0.029226 0.1765 0.02728 0.1761 
cg09361691 -0.1354 0.03219 0.38628 -0.3527 0.001296 0.015552 0.0408 0.6169 0.9396 
cg11514288 0.0015 0.9795 0.9857 -0.1098 0.2933 0.43995 0.0407 0.5913 0.9396 
cg12089079 -0.0781 0.2738 0.8214 -0.2426 0.08768 0.210432 -0.0283 0.7408 0.9396 
cg12367389 0.0055 0.9411 0.9857 -0.0061 0.9661 0.9661 -0.0068 0.9396 0.9396 
cg14059288 -0.1516 0.1409 0.7188 -0.2898 0.1119 0.2238 0.2735 0.02935 0.1761 
cg15894389 -0.0171 0.7837 0.9857 -0.1105 0.2905 0.43995 0.0515 0.5294 0.9396 
cg16188532 -0.0779 0.1797 0.7188 -0.2064 0.03577 0.14308 -0.0227 0.7607 0.9396 
cg20102280 -0.0093 0.8987 0.9857 -0.0619 0.6432 0.701673 0.1157 0.2079 0.8316 
cg26950475 -0.0013 0.9857 0.9857 -0.0998 0.3847 0.512933 -0.0196 0.8505 0.9396 
 
NPSR1 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00081087 -0.0708 0.3385 0.866125 -0.0697 0.5941 0.965413 -0.0105 0.9111 0.9111 
cg03382549 0.1207 0.1725 0.866125 0.0056 0.9706 0.9706 0.2105 0.05748 0.24908 
cg05399607 0.0043 0.9622 0.9622 -0.21 0.1605 0.6435 0.1293 0.2702 0.71916 
cg06506864 0.0469 0.3728 0.866125 -0.0798 0.3933 0.748614 0.1704 0.007977 0.09581 
cg08251685 -0.0691 0.4108 0.866125 -0.0245 0.8733 0.9706 0.0175 0.8675 0.9111 
cg15754660 0.0855 0.09754 0.866125 0.1037 0.2475 0.6435 0.071 0.2766 0.71916 
cg17744825 -0.0339 0.722 0.9386 0.0176 0.9133 0.9706 0.119 0.3397 0.736017 
cg19194095 0.0039 0.9622 0.9622 -0.1729 0.2049 0.6435 0.0873 0.4303 0.799129 
cg20495677 0.0635 0.3644 0.866125 0.0068 0.9536 0.9706 0.0213 0.8139 0.9111 
cg20842782 -0.0159 0.8542 0.9622 0.1281 0.4031 0.748614 0.0262 0.8106 0.9111 
cg23448390 -0.0662 0.533 0.866125 -0.4318 0.02289 0.29757 0.0512 0.6924 0.9111 
cg23862011 0.0454 0.6039 0.8723 -0.0116 0.9414 0.9706 0.038 0.7336 0.9111 
cg24929847 0.0733 0.4825 0.866125 -0.3039 0.08601 0.559065 0.3266 0.01474 0.09581 
 
OXTR 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00078085 -0.0551 0.3384 0.661556 0.0346 0.7427 0.881282 -0.0451 0.5208 0.9555 
cg00385883 0.162 0.1131 0.661556 -0.0794 0.6432 0.881282 0.3078 0.02286 0.169975 
cg02192228 0.088 0.1461 0.661556 0.0399 0.6974 0.881282 -0.0012 0.9884 0.9884 
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cg03987506 -0.0473 0.4157 0.661556 0.0186 0.8568 0.9273 -0.0361 0.6191 0.9555 
cg04523291 0.0508 0.3698 0.661556 -0.0093 0.9273 0.9273 0.1559 0.02615 0.169975 
cg08535600 0 0.9995 0.9995 -0.1099 0.2265 0.881282 0.0181 0.7881 0.9555 
cg09353063 0.0666 0.2741 0.661556 0.0388 0.7329 0.881282 0.0472 0.541 0.9555 
cg12695586 -0.0267 0.6667 0.733092 -0.1694 0.1618 0.881282 0.0337 0.6621 0.9555 
cg15317815 0.0197 0.6767 0.733092 0.034 0.6542 0.881282 0.1222 0.05432 0.235387 
cg17285225 -0.0627 0.2339 0.661556 -0.0337 0.7149 0.881282 -0.0261 0.6983 0.9555 
cg19619174 0.0986 0.2742 0.661556 -0.2726 0.07895 0.881282 0.1683 0.132 0.429 
cg23391006 -0.0601 0.458 0.661556 0.048 0.7457 0.881282 -0.0249 0.8162 0.9555 
cg27501759 -0.0199 0.5233 0.68029 0.0178 0.7278 0.881282 0.0061 0.882 0.9555 
 
SGK1 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg00959636 -0.3081 0.000787 0.035424 -0.0941 0.5429 0.939635 -0.0021 0.9856 0.9856 
cg01059669 -0.1247 0.1967 0.5901 0.1557 0.337 0.871816 -0.1666 0.1743 0.6678 
cg02904344 0.0517 0.5148 0.858 0.1559 0.2766 0.871816 0.0453 0.6538 0.8406 
cg03146155 0.0765 0.2543 0.6585 -0.0719 0.5347 0.939635 -0.0878 0.2901 0.713045 
cg03400131 -0.0144 0.8348 0.9684 0.02 0.8799 0.960239 0.0422 0.6169 0.824824 
cg03762694 -0.1551 0.05531 0.3957 0.1272 0.3681 0.871816 -0.1048 0.3082 0.713045 
cg03944089 0.0093 0.8968 0.9684 -0.0517 0.6711 0.953743 0.0929 0.3133 0.713045 
cg04060943 0.0431 0.6092 0.877091 -0.1797 0.2277 0.871816 0.0985 0.3486 0.713045 
cg04905719 -0.0536 0.3023 0.680175 -0.0263 0.7418 0.953743 -0.085 0.2081 0.6678 
cg05183646 -0.0835 0.1623 0.521679 -0.2501 0.02184 0.480488 -0.0899 0.2205 0.6678 
cg05966641 0.0029 0.9684 0.9684 -0.2313 0.07036 0.63324 -0.0256 0.7723 0.923566 
cg06358608 -0.0329 0.6432 0.877091 0.0762 0.5397 0.939635 0.0724 0.427 0.7686 
cg06642177 0.0945 0.007257 0.163283 0.0159 0.7968 0.960239 0.0319 0.494 0.793929 
cg06849960 -0.1124 0.2532 0.6585 -0.2079 0.2853 0.871816 -0.1347 0.2537 0.713045 
cg07340870 0.2117 0.05854 0.3957 0.2113 0.2364 0.871816 0.2343 0.1282 0.6678 
cg08239804 0.0299 0.7262 0.961147 -0.297 0.03905 0.480488 -0.0556 0.6232 0.824824 
cg08550353 0.0321 0.6409 0.877091 0.1066 0.3565 0.871816 0.0638 0.468 0.788167 
cg08640361 0.1429 0.1342 0.50325 0.0185 0.9075 0.960239 -0.1126 0.3455 0.713045 
cg08647910 -0.0548 0.4741 0.826442 -5.00E-04 0.9974 0.9974 -0.0064 0.9465 0.9856 
cg08698685 0.0084 0.8757 0.9684 -0.0367 0.6733 0.953743 0.0174 0.8055 0.929423 
cg09315391 -0.004 0.9668 0.9684 -0.112 0.447 0.939635 0.0928 0.4729 0.788167 
cg09404376 0.1271 0.0718 0.3957 0.101 0.416 0.936 0.1743 0.05934 0.5841 
cg09872934 -0.0159 0.8251 0.9684 -0.1379 0.2846 0.871816 -0.0184 0.8376 0.9423 
cg10105971 -0.0449 0.6336 0.877091 -0.0271 0.8566 0.960239 -0.0832 0.5142 0.797897 
cg11856561 0.0101 0.9266 0.9684 -0.2646 0.1481 0.833063 0.1756 0.2106 0.6678 
cg12009778 0.0321 0.7607 0.9684 -0.3621 0.04271 0.480488 0.2384 0.07788 0.5841 
cg13307058 0.1 0.09686 0.43587 0.0762 0.5068 0.939635 0.0021 0.9774 0.9856 
cg14905466 0.0363 0.5627 0.877091 0.0397 0.7217 0.953743 0.0038 0.9607 0.9856 
cg17284168 -0.0591 0.5934 0.877091 0.0893 0.6447 0.953743 -0.0827 0.5454 0.8181 
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cg17689707 -0.1106 0.158 0.521679 0.0208 0.8779 0.960239 -0.0498 0.6197 0.824824 
cg18566177 0.0087 0.9256 0.9684 -0.012 0.9389 0.960239 0.0361 0.7638 0.923566 
cg20393620 -0.0121 0.8861 0.9684 0.0443 0.7363 0.953743 0.0178 0.8794 0.965195 
cg20655113 0.0267 0.7832 0.9684 0.0691 0.7113 0.953743 0.1472 0.2075 0.6678 
cg20822858 -0.0811 0.4775 0.826442 0.0205 0.9191 0.960239 0.169 0.2226 0.6678 
cg21064939 -0.1945 0.04844 0.3957 -0.2798 0.1248 0.833063 -0.3021 0.0128 0.192 
cg21078322 0.0748 0.3227 0.6915 -0.0365 0.7874 0.960239 -0.085 0.3702 0.724304 
cg21366688 0.0704 0.3438 0.703227 -0.0606 0.627 0.953743 0.1606 0.09767 0.627879 
cg21676440 -0.1223 0.2896 0.680175 -0.2162 0.2948 0.871816 -0.2585 0.07001 0.5841 
cg21834463 0.037 0.4706 0.826442 -0.0832 0.3456 0.871816 -0.1629 0.01225 0.192 
cg23347562 0.0789 0.457 0.826442 -0.0389 0.8407 0.960239 0.1646 0.2177 0.6678 
cg24688636 -0.1439 0.06378 0.3957 -0.2034 0.1302 0.833063 -0.2642 0.006513 0.192 
cg25025235 -0.0972 0.2634 0.6585 -0.095 0.5276 0.939635 -0.0643 0.5671 0.82321 
cg25661219 -0.156 0.07914 0.3957 -0.3501 0.03569 0.480488 -0.0299 0.7799 0.923566 
cg26557834 0.1684 0.03655 0.3957 0.1328 0.3486 0.871816 0.1004 0.3188 0.713045 
cg27289153 0.1291 0.1258 0.50325 -0.0731 0.6134 0.953743 0.0838 0.423 0.7686 
 
TMEM132D 
 Whole Males Females 
Probe Beta P-value FDR (Gene) Beta P-value FDR (Gene) Beta P-value FDR (Gene) 
cg01163404 0.1089 0.1225 0.601033 0.2281 0.05266 0.410459 0.0125 0.8917 0.9854 
cg01202700 0.2627 0.01158 0.211335 0.3553 0.05984 0.410459 0.2938 0.02614 0.432744 
cg01831527 -0.0222 0.7099 0.94071 0.0595 0.5857 0.92345 -0.0815 0.2604 0.746164 
cg02365079 0.1364 0.04654 0.283118 0.2054 0.08221 0.500111 0.0107 0.9031 0.9854 
cg02767665 0.0241 0.7505 0.94071 0.0209 0.8775 0.957934 0.0881 0.3673 0.812512 
cg03283235 -0.0326 0.6895 0.94071 0.0119 0.9325 0.9775 -0.0019 0.9854 0.9854 
cg03420866 -0.0508 0.537 0.94071 0.1719 0.2448 0.770758 -0.0181 0.8623 0.9854 
cg03469054 0.0441 0.4531 0.94071 -0.0715 0.5112 0.92345 0.1036 0.1493 0.746164 
cg03685843 -0.0021 0.9685 0.981951 -0.1253 0.2045 0.746425 -0.0747 0.2763 0.746164 
cg04386563 -0.0081 0.8993 0.976613 -0.117 0.2773 0.778573 0.0609 0.4494 0.849815 
cg04414975 -0.081 0.3413 0.94071 -0.307 0.02555 0.410459 -0.0691 0.5355 0.849815 
cg04729491 0.0398 0.7088 0.94071 -0.0291 0.8782 0.957934 -0.0106 0.9377 0.9854 
cg04925956 0.0389 0.5332 0.94071 -0.0241 0.8394 0.957934 -0.0518 0.4992 0.849815 
cg05160910 0.0375 0.6074 0.94071 0.2321 0.06185 0.410459 0.0973 0.3156 0.794441 
cg05384697 -0.1853 0.04234 0.280984 -0.1445 0.4073 0.838892 -0.1897 0.08699 0.58473 
cg05479657 0.0645 0.4126 0.94071 -0.0498 0.6908 0.92345 -0.0398 0.6969 0.97721 
cg05742082 -0.0227 0.7898 0.960923 -0.0993 0.564 0.92345 0.0962 0.3383 0.796642 
cg06200996 -0.0308 0.5584 0.94071 -0.0505 0.5793 0.92345 -0.0432 0.5236 0.849815 
cg06679878 -0.0165 0.8482 0.967478 -0.3303 0.02196 0.410459 -0.2043 0.06154 0.546364 
cg07056260 -0.0643 0.3118 0.94071 -0.1391 0.1953 0.746425 -0.0224 0.7859 0.97721 
cg07067993 -0.0376 0.4332 0.94071 -0.0713 0.3777 0.838892 0.0873 0.1595 0.746164 
cg07230440 0.0776 0.1235 0.601033 0.0329 0.7351 0.941444 -0.0527 0.3882 0.819269 
cg07350016 0.0513 0.5975 0.94071 -0.0794 0.6195 0.92345 0.039 0.7624 0.97721 
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cg08261450 0.0405 0.5438 0.94071 -0.1287 0.2721 0.778573 -0.0408 0.6287 0.936635 
cg08546107 -0.0013 0.9872 0.9872 -0.1925 0.2152 0.748076 0.1208 0.2362 0.746164 
cg09044656 0.0068 0.9204 0.976613 0.0904 0.4137 0.838892 0.0965 0.2862 0.746164 
cg10639585 0.028 0.6388 0.94071 0.046 0.6713 0.92345 0.0061 0.9347 0.9854 
cg11023224 0.0052 0.9411 0.981433 -0.1195 0.3893 0.838892 0.1089 0.1996 0.746164 
cg11160362 0.108 0.6069 0.94071 0.0122 0.9699 0.9775 -0.2488 0.3928 0.819269 
cg11230248 0.0825 0.2952 0.94071 0.1943 0.1686 0.733865 0.0137 0.89 0.9854 
cg11496226 -0.1054 0.02166 0.225883 -0.0574 0.4759 0.890787 -0.1544 0.006169 0.225169 
cg12072740 -0.0412 0.5541 0.94071 -0.2433 0.04073 0.410459 -0.0985 0.266 0.746164 
cg12820134 0.0178 0.8193 0.967478 -0.1296 0.3286 0.814923 -0.0641 0.529 0.849815 
cg13090220 0.1599 0.04151 0.280984 0.1352 0.3276 0.814923 0.1136 0.2506 0.746164 
cg13123585 -0.0419 0.5674 0.94071 -0.1381 0.2477 0.770758 0.003 0.9756 0.9854 
cg13916352 -0.0723 0.4593 0.94071 -0.1895 0.2534 0.770758 -0.0561 0.6555 0.93898 
cg14504768 -0.0147 0.8417 0.967478 0.071 0.5863 0.92345 0.0547 0.5513 0.856274 
cg14918019 0.0365 0.6602 0.94071 -0.0041 0.9775 0.9775 0.0093 0.9281 0.9854 
cg15617706 0.2868 0.005854 0.142447 0.0345 0.8459 0.957934 0.2738 0.0431 0.524383 
cg15936861 0.0317 0.718 0.94071 -0.2418 0.1079 0.562621 0.1396 0.2007 0.746164 
cg16048915 0.056 0.4032 0.94071 -0.0314 0.788 0.957934 0.0605 0.4764 0.849815 
cg16533379 0.0551 0.3138 0.94071 0.0192 0.8424 0.957934 0.0035 0.9588 0.9854 
cg17157798 -0.0147 0.8296 0.967478 -0.1897 0.1064 0.562621 0.0837 0.3527 0.804597 
cg17186073 -0.0772 0.09916 0.556822 -0.112 0.1709 0.733865 -0.047 0.4626 0.849815 
cg17444697 0.0559 0.3957 0.94071 0.0451 0.7068 0.92345 0.0866 0.2815 0.746164 
cg17513770 0.0176 0.7401 0.94071 -0.0047 0.9605 0.9775 0.104 0.1184 0.720267 
cg17718276 -0.0548 0.3384 0.94071 0.2271 0.04171 0.410459 -0.0024 0.972 0.9854 
cg17735631 0.0077 0.9231 0.976613 0.1239 0.3474 0.818071 0.0746 0.4832 0.849815 
cg17883960 0.031 0.6779 0.94071 -0.0057 0.9644 0.9775 0.0627 0.5133 0.849815 
cg18180056 0.0718 0.4296 0.94071 -0.1 0.5439 0.92345 0.0359 0.7525 0.97721 
cg18437033 -0.0617 0.5145 0.94071 -0.0232 0.8792 0.957934 0.0698 0.5676 0.863225 
cg18723572 0.166 0.01526 0.214377 0.0948 0.4355 0.853908 0.2139 0.01315 0.319983 
cg18758559 0.0026 0.9648 0.981951 0.0885 0.4003 0.838892 -0.0786 0.2807 0.746164 
cg19070138 0.1849 0.001056 0.077088 0.1522 0.1168 0.568427 -0.0032 0.9649 0.9854 
cg19700087 0.0244 0.6669 0.94071 0.0375 0.7084 0.92345 0.1107 0.1331 0.746164 
cg19790509 0.0827 0.2906 0.94071 -0.0765 0.5785 0.92345 0.0718 0.4571 0.849815 
cg20168964 0.0867 0.1801 0.730406 0.027 0.8083 0.957934 -0.0264 0.7513 0.97721 
cg20327057 0.2712 0.003043 0.11107 0.0846 0.6043 0.92345 0.2435 0.02964 0.432744 
cg20470734 0.048 0.4505 0.94071 -0.194 0.05933 0.410459 0.0168 0.8443 0.9854 
cg21903395 -0.0221 0.6757 0.94071 0.0363 0.7003 0.92345 0.0197 0.7755 0.97721 
cg23266743 -0.0606 0.4741 0.94071 -0.0486 0.7506 0.944721 -0.0156 0.8861 0.9854 
cg23733052 0.19 0.03625 0.280984 -0.1412 0.3326 0.814923 0.0758 0.5326 0.849815 
cg23805623 0.0288 0.5975 0.94071 -0.181 0.06041 0.410459 0.0655 0.3302 0.796642 
cg23917477 -0.0209 0.7603 0.94071 0.0514 0.6656 0.92345 0.2477 0.004213 0.225169 
cg24008358 0.0659 0.1666 0.7154 0.1575 0.06094 0.410459 -0.0162 0.7898 0.97721 
cg25015139 -0.0301 0.6985 0.94071 -0.1862 0.1872 0.746425 0.1165 0.231 0.746164 
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cg25102216 0.1816 0.02538 0.231593 -0.029 0.8573 0.957934 0.1068 0.2708 0.746164 
cg25625370 0.0714 0.1421 0.648331 0.0379 0.6591 0.92345 0.1122 0.06271 0.546364 
cg26322591 -0.0173 0.7326 0.94071 -0.2447 0.009236 0.410459 0.1045 0.08811 0.58473 
cg26364947 0.0555 0.2 0.768421 -0.0056 0.9423 0.9775 0.0241 0.656 0.93898 
cg26411747 0.2294 0.01762 0.214377 0.1354 0.4445 0.853908 0.1603 0.1791 0.746164 
cg26614129 0.0106 0.8801 0.976613 0.0496 0.686 0.92345 -0.1679 0.06736 0.546364 
cg27463181 0.0093 0.892 0.976613 0.1093 0.3349 0.814923 -0.031 0.7374 0.97721 
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Supplementary Figure 1. 
Multidimensional scaling (MDS) plots used to investigate population structure in 
the MPIP Panic Cohort I (discovery sample).  
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Supplementary Figure 2. 
Multidimensional scaling (MDS) plots used to investigate population structure in 
the MPIP Panic Cohort II (replication sample).  
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Supplementary Figure 3. Correlation plot for the MPIP Panic Cohort I-MDD data 
(N=699) after normalization, before batch correction, with the surrogate 
variables.  
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Supplementary Figure 4. QQ-plots of p-values for the MPIP Panic Cohort I 
(discovery sample).  
Theoretical vs observed distributions for all the 424,834 p-values from the case-
control analysis, males only.  
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Supplementary Figure 5. QQ-plots of p-values for the MPIP Panic Cohort I 
(discovery sample).  
Theoretical vs observed distributions for all the 424,834 p-values from the case-
control analysis, females only.  
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Supplementary Figure 6. QQ-plots of p-values for the MPIP Panic Cohort II 
(replication sample).  
Theoretical vs observed distributions for all 425,119 p-values from the case-
control analysis, whole sample. 
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Supplementary Figure 7. QQ-plots of p-values for the MPIP Panic Cohort II 
(replication sample).  
Theoretical vs observed distributions for all 425,119 p-values from the case-
control analysis, males only. 
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Supplementary Figure 8. QQ-plots of p-values for the MPIP Panic Cohort II 
(replication sample).  
Theoretical vs observed distributions for all 425,119 p-values from the case-
control analysis, females only.  
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Supplementary Figure 9. HECA Gene Expression in Tissues 
Expression values are shown in RPKM (Reads Per Kilobase of transcript per 
Million mapped reads). Box plots are shown as median and 25th and 75th 
percentiles; points are displayed as outliers if they are above or below 1.5 times 
the interquartile range. Data Source: GTEx Analysis Release V6p (dbGaP 
Accession phs000424.v6.p1) (http://www.gtexportal.org/home/)  
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Supplementary Figure 10. Correlation of HECA methylation levels at the 
cg07308824 locus in whole blood and four brain regions in a linear regression 
model. The top panel is a boxplot with the DNA methylation levels per tissue 
type. Upper left panel: prefrontal cortex (PFC); lower left panel: superior 
temporal gyrus (STG); upper right panel: entorhinal cortex (EC); lower right 
panel: cerebellum (CER) (http://epigenetics.iop.kcl.ac.uk/bloodbrain/). 
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